Details of the Drug

General Information of Drug (ID: DM53SRA)

Drug Name
Prochlorperazine
Synonyms
CHLOPERAZINE; Capazine; Chlormeprazine; Chlorperazine; Combid; Compazine; Compro; Emelent; Eskatrol; Kronocin; Meterazin; Meterazine; Nipodal; Novamin; Prochloroperazine; Prochlorpemazine; Prochlorperazin; Prochlorperazinum; Prochlorpermazine; Prochlorpromazine; Procloperazine; Proclorperazina; Proclorperazine; Stemetil; Tementil; Temetid; Vertigon; Compazine Suppositories; Prochlorperazine Edisylate Salt; Prochlorperazine dihydrobromide; Prochlorperazine dimaleate; Prochlorperazine maleate; Prochlorperazine mesilate; Bayer A 173; P77; RP 6140; SKF 4657; Buccastem (TN); Compazine (TN); Compro (TN); Phenotil (TN); Prochlorperazinum [INN-Latin]; Proclorperazina [INN-Spanish]; Stemetil (TN); Stemzine (TN); Compazine (*Maleate*); Prochlorperazine (JAN/USP/INN); Prochlorperazine [USAN:INN:BAN:JAN]; Chloro-3 (N-methylpiperazinyl-3 propyl)-10 phenothiazine; Chloro-3 (N-methylpiperazinyl-3 propyl)-10 phenothiazine [French]; N-(gamma-(4'-Methylpiperazinyl-1')propyl)-3-chlorophenothiazine; 2-Chloro-10-(3-(1-methyl-4-piperazinyl)propyl)-phenothiazine; 2-Chloro-10-(3-(4-methyl-1-piperazinyl)propyl)-10H-phenothiazine; 2-Chloro-10-(3-(4-methyl-1-piperazinyl)propyl)phenothiazine; 2-Chloro-10-[3-(4-methyl-1-piper-azinyl)propyl]-10H-pheno-thiazine dimaleate; 2-chloro-10-[3-(4-methylpiperazin-1-yl)propyl]-10H-phenothiazine; 2-chloro-10-[3-(4-methylpiperazin-1-yl)propyl]phenothiazine; 3-Chloro-10-(3-(1-methyl-4-piperazinyl)propyl)phenothiazine; 3-Chloro-10-(3-(4-methyl-1-piperazinyl)propyl)phenothiazine; 6140 RP
Indication
Disease Entry ICD 11 Status REF
Nausea MD90 Approved [1]
Therapeutic Class
Antipsychotic Agents
Affected Organisms
Humans and other mammals
ATC Code
N05AB04: Prochlorperazine
N05AB: Phenothiazines with piperazine structure
N05A: ANTIPSYCHOTICS
N05: PSYCHOLEPTICS
N: NERVOUS SYSTEM
N05AB04: Prochlorperazine
N05AB: Phenothiazines with piperazine structure
N05A: ANTIPSYCHOTICS
N05: PSYCHOLEPTICS
N: NERVOUS SYSTEM
N05AB04: Prochlorperazine
N05AB: Phenothiazines with piperazine structure
N05A: ANTIPSYCHOTICS
N05: PSYCHOLEPTICS
N: NERVOUS SYSTEM
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 373.9
Logarithm of the Partition Coefficient (xlogp) 4.9
Rotatable Bond Count (rotbonds) 4
Hydrogen Bond Donor Count (hbonddonor) 0
Hydrogen Bond Acceptor Count (hbondacc) 4
ADMET Property
Absorption Tmax
The time to maximum plasma concentration (Tmax) is 5 h [2]
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 1: high solubility and high permeability [3]
Bioavailability
The bioavailability of drug is 12.5% [2]
Clearance
The renal clearance of drug is 23.6 mL/h [4]
Elimination
0.1% of drug is excreted from urine in the unchanged form [3]
Half-life
The concentration or amount of drug in body reduced by one-half in 9 - 8 hours [4]
Metabolism
The drug is metabolized via the hepatic [5]
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 3.828 micromolar/kg/day [6]
Vd
The volume of distribution (Vd) of drug is 1401 L [7]
Water Solubility
The ability of drug to dissolve in water is measured as 0.1 mg/mL [3]
Adverse Drug Reaction (ADR)
ADR Term Variation Related DOT DOT ID REF
Metabolic disorder Not Available UGT1A1 OTH1C8OJ [8]
Metabolic disorder Not Available G6PC OTJ6FM9F [8]
Chemical Identifiers
Formula
C20H24ClN3S
IUPAC Name
2-chloro-10-[3-(4-methylpiperazin-1-yl)propyl]phenothiazine
Canonical SMILES
CN1CCN(CC1)CCCN2C3=CC=CC=C3SC4=C2C=C(C=C4)Cl
InChI
InChI=1S/C20H24ClN3S/c1-22-11-13-23(14-12-22)9-4-10-24-17-5-2-3-6-19(17)25-20-8-7-16(21)15-18(20)24/h2-3,5-8,15H,4,9-14H2,1H3
InChIKey
WIKYUJGCLQQFNW-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
4917
ChEBI ID
CHEBI:8435
CAS Number
58-38-8
UNII
YHP6YLT61T
DrugBank ID
DB00433
TTD ID
D0B2UZ
VARIDT ID
DR00592
INTEDE ID
DR1345
ACDINA ID
D00559
Combinatorial Drugs (CBD) Click to Jump to the Detailed CBD Information of This Drug
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Dopamine D2 receptor (D2R) TTEX248 DRD2_HUMAN Antagonist [9]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 2D6 (CYP2D6)
Main DME 		DECB0K3 CP2D6_HUMAN Substrate [10]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
Glucose-6-phosphatase catalytic subunit 1 (G6PC1) OTJ6FM9F G6PC1_HUMAN Drug Response [8]
Transcription factor EB (TFEB) OTJUJJQY TFEB_HUMAN Protein Interaction/Cellular Processes [11]
UDP-glucuronosyltransferase 1A1 OTH1C8OJ UD11_HUMAN Drug Response [8]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Nausea
ICD Disease Classification MD90
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Dopamine D2 receptor (D2R) DTT DRD2 2.50E-02 -0.08 -0.49
Cytochrome P450 2D6 (CYP2D6) DME CYP2D6 7.30E-01 -1.91E-02 -1.41E-01
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

Experimental Cancer Drug Sensitivity Information

Cancer Drug Sensitivity Data Curated from 141 Cell Line(s) in Haematopoietic And Lymphoid Tissue Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
JK1 CTRP2 3.3023 5.6339 3.1532 18.7822
MEC1 CTRP2 5.0617 6.2348 4.9145 7.0711
JM1 CTRP2 4.1767 5.599 4.1081 12.6774
EoL-1 CTRP2 1.9901 2.7713 1.9901 27.0102
Pfeiffer CTRP2 2.3323 3.7162 2.3288 24.7423
Ri-1 CTRP2 2.5663 5.1118 2.4565 23.5455
Daudi CTRP2 2.6192 3.6682 2.6184 22.8217
MOTN-1 CTRP2 2.6473 4.5297 2.6154 22.7393
K-562 CTRP2 2.6888 3.896 2.6863 22.3639
ST486 CTRP2 2.7526 4.0748 2.7475 21.9473
GA-10 CTRP2 2.7625 3.9834 2.7595 21.8746
MOLT-3 CTRP2 2.8115 3.3803 2.8115 21.5383
LP-1 CTRP2 2.8272 4.4118 2.8107 21.4887
AML-193 CTRP2 2.9503 3.6117 2.9502 20.6137
TALL-1 [Human adult T-ALL] CTRP2 2.9877 5.2465 2.8876 20.706
Peer CTRP2 3.0341 4.5775 3.015 20.1192
Ku812 CTRP2 3.0629 4.7454 3.0324 19.9657
NALM-6 CTRP2 3.152 5.0336 3.0955 19.4609
SUP-T11 CTRP2 3.1699 5.2896 3.0765 19.4689
KMS-21-BM CTRP2 3.2112 4.4369 3.2043 18.8983
DND-41 CTRP2 3.2349 4.6851 3.2164 18.7794
KE-37 CTRP2 3.2557 4.4443 3.2495 18.5994
SU-DHL-1 CTRP2 3.4827 5.1559 3.4317 17.2389
NCO2 CTRP2 3.484 4.8723 3.4624 17.1304
KHM-1B CTRP2 3.5252 4.9011 3.5032 16.8574
JURL-MK1 CTRP2 3.5612 5.5825 3.4451 16.9424
Hs 611.T CTRP2 3.5773 5.2891 3.5142 16.6505
Ki-JK CTRP2 3.5815 5.1273 3.5403 16.5476
RPMI-8402 CTRP2 3.601 5.2684 3.5426 16.4765
CML-T1 CTRP2 3.6182 4.7327 3.6097 16.1921
F-36P CTRP2 3.6489 5.4333 3.568 16.2355
MJ CTRP2 3.6626 18.8811 -2.453 33.689
MOLT-16 CTRP2 3.6706 5.2902 3.614 16.0069
Granta-519 CTRP2 3.6711 5.4819 3.5834 16.111
MOLM-6 CTRP2 3.7645 5.42 3.6948 15.4266
P12-Ichikawa CTRP2 3.7663 5.3853 3.7023 15.3948
PF-382 CTRP2 3.8193 5.3843 3.7593 15.028
KMS-26 CTRP2 3.8208 4.8909 3.8108 14.8474
KMS-28BM CTRP2 3.8635 5.6056 3.7682 14.8564
MOLP-8 CTRP2 3.8729 6.0173 3.6819 15.1344
KMS-20 CTRP2 3.935 4.9834 3.9237 14.0909
M-07e CTRP2 3.9744 5.1721 3.9505 13.8712
KCL-22 CTRP2 3.9972 6.0734 3.8022 14.3217
697 CTRP2 4.0616 5.3299 4.0255 13.3317
L-428 CTRP2 4.0691 5.5305 4.0041 13.3815
KM-H2 CTRP2 4.0813 6.6033 3.727 14.3491
P31/FUJ CTRP2 4.0846 5.6867 3.9916 13.3759
KMS-11 CTRP2 4.0894 5.6789 3.9984 13.337
SU-DHL-4 CTRP2 4.0911 6.2844 3.8426 13.8922
NU-DUL-1 CTRP2 4.1009 10.4138 0.9355 14.9734
AMO1 CTRP2 4.1339 5.4742 4.0829 12.9016
Raji CTRP2 4.1448 5.4376 4.0999 12.8078
KMS-12-BM CTRP2 4.1453 5.5219 4.0876 12.8488
LAMA-84 CTRP2 4.1477 5.7402 4.049 12.976
EM-2 CTRP2 4.1494 5.4865 4.0976 12.8008
Reh CTRP2 4.1532 5.4987 4.0998 12.7813
Jurkat CTRP2 4.154 5.7444 4.0549 12.9354
A4/Fukuda CTRP2 4.1635 5.3633 4.1297 12.6453
HT CTRP2 4.1644 5.0983 4.1543 12.5584
RPMI-8226 CTRP2 4.1651 8.8671 2.8706 17.4436
HDLM-2 CTRP2 4.1698 6.9647 3.6901 14.2362
SEM CTRP2 4.1787 4.9265 4.1759 12.4387
SUP-M2 CTRP2 4.1796 5.0157 4.1739 12.4426
Kasumi-2 CTRP2 4.19 5.5571 4.1298 12.5594
SU-DHL-6 CTRP2 4.2024 6.1373 4.0081 12.9547
KMS-34 CTRP2 4.2078 5.3938 4.173 12.3534
RS4;11 CTRP2 4.2131 5.8188 4.1026 12.5822
OCI-AML-3 CTRP2 4.2209 5.3973 4.1865 12.2646
PL21 CTRP2 4.2219 5.347 4.1936 12.2372
DEL CTRP2 4.2427 4.941 4.2405 12.0104
SK-MM-2 CTRP2 4.2883 6.0134 4.1363 12.2299
SU-DHL-8 CTRP2 4.2898 6.1778 4.0915 12.3881
Mono-Mac-1 CTRP2 4.2928 5.8963 4.1712 12.0912
MHH-CALL-4 CTRP2 4.2969 5.3375 4.2739 11.7196
MOLM-13 CTRP2 4.3036 6.3494 4.0533 12.4868
HEL CTRP2 4.3075 6.5216 4 12.6738
GDM-1 CTRP2 4.3106 5.7641 4.2208 11.8602
SU-DHL-10 CTRP2 4.3266 6.4007 4.0616 12.3884
RCH-ACV CTRP2 4.3441 5.8022 4.2489 11.6562
DB CTRP2 4.3601 5.7304 4.2815 11.4913
L-363 CTRP2 4.3715 5.5318 4.3288 11.29
BL-70 CTRP2 4.3732 5.4491 4.342 11.2391
HuNS1 CTRP2 4.3797 6.5717 4.0605 12.2383
KMS-27 CTRP2 4.3804 5.3963 4.3558 11.1687
WSU-DLCL2 CTRP2 4.3819 4.9618 4.3809 11.079
MV4-11 CTRP2 4.382 5.8088 4.2887 11.397
L-540 CTRP2 4.384 5.4745 4.3502 11.1761
KE-97 CTRP2 4.3937 5.0485 4.3914 11.005
NCI-H929 CTRP2 4.4048 6.9214 3.9574 12.5579
SKM-1 CTRP2 4.4106 5.3757 4.3898 10.9544
THP-1 CTRP2 4.4172 5.7226 4.345 11.0883
HuT 78 CTRP2 4.4202 5.7864 4.3351 11.1138
KMS-18 CTRP2 4.4533 5.2497 4.4444 10.63
SR CTRP2 4.4583 5.7433 4.3853 10.8175
Karpas-299 CTRP2 4.469 6.8454 4.0553 12.0046
MM1.S CTRP2 4.4714 7.3751 3.8434 12.8173
NU-DHL-1 CTRP2 4.5084 5.1664 4.5049 10.2445
Mono-Mac-6 CTRP2 4.5162 6.1039 4.36 10.7292
REC-1 CTRP2 4.5326 5.8474 4.4439 10.3782
HPB-ALL CTRP2 4.5567 5.636 4.5114 10.0656
JJN-3 CTRP2 4.5666 5.1131 4.5653 9.8497
A3/Kawakami CTRP2 4.5899 5.0063 4.5897 9.6907
BV-173 CTRP2 4.6019 6.0894 4.4577 10.1159
NB4 CTRP2 4.6345 5.6396 4.5944 9.5296
Karpas-422 CTRP2 4.6522 6.8241 4.2586 10.7159
U266B1 CTRP2 4.6524 5.3378 4.6453 9.2972
ME1 CTRP2 4.6773 8.118 3.7264 12.7474
KYO-1 CTRP2 4.7024 5.4921 4.6856 8.9974
EHEB CTRP2 4.7575 9.6504 3.0819 15.15
JVM-3 CTRP2 4.7791 12.282 1.8171 19.9692
U-937 CTRP2 4.8253 5.9313 4.7431 8.4066
CA46 CTRP2 4.9234 6.1494 4.7908 7.9358
JeKo-1 CTRP2 5.0531 6.0243 4.968 6.9011
SUP-HD1 CTRP2 5.073 6.4919 4.8356 7.3346
OCI-Ly10 CTRP2 5.0778 7.3428 4.4816 8.7085
Karpas-620 CTRP2 5.0851 6.2633 4.9305 6.9429
SET-2 CTRP2 5.1079 6.5794 4.8391 7.2238
Namalwa CTRP2 5.1099 6.0611 5.0199 6.541
HD-MY-Z CTRP2 5.1131 6.3479 4.9316 6.8575
Kasumi-1 CTRP2 5.1281 6.2154 4.993 6.5851
MHH-CALL-3 CTRP2 5.1583 6.2604 5.0109 6.4303
RL CTRP2 5.1911 7.2251 4.6492 7.7502
KMM-1 CTRP2 5.1953 8.3383 4.1308 9.8471
OCI-Ly3 CTRP2 5.1993 6.8461 4.825 7.031
OCI-AML-5 CTRP2 5.2252 5.8615 5.1928 5.5686
EJM CTRP2 5.2401 6.6601 4.9461 6.4481
OCI-Ly19 CTRP2 5.2421 7.0974 4.7584 7.184
SUP-B15 CTRP2 5.2465 6.666 4.9503 6.4145
HL-60 CTRP2 5.2621 6.2 5.1436 5.6341
HEL 92.1.7 CTRP2 5.2665 5.9318 5.2233 5.3316
TF-1 CTRP2 5.2736 5.9573 5.2253 5.3023
MOLM-16 CTRP2 5.3493 10.3588 3.2836 12.9913
KO52 CTRP2 5.3681 5.9077 5.3387 4.6064
RPMI-6666 CTRP2 5.4033 6.1002 5.3287 4.5342
MOLP-2 CTRP2 5.4072 6.5604 5.1625 5.1544
SIG-M5 CTRP2 5.5115 5.9091 5.4934 3.612
OCI-M1 CTRP2 5.5242 6.0665 5.4705 3.654
CMK CTRP2 5.5928 5.9705 5.5696 3.0883
Ci-1 CTRP2 5.6039 5.9822 5.5791 3.0204
P3HR-1 CTRP2 5.7684 8.7317 4.4644 7.1938
MC116 CTRP2 7.3375 8.2614 5.7433 0.1265
⏷ Show the Full List of 141 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 24 Cell Line(s) in Oesophagus Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
TE8 CTRP2 4.3325 5.5104 4.2902 11.5488
TE15 CTRP2 5.3056 6.9325 4.8966 6.47
TE-4 CTRP2 3.4075 5.2192 3.3427 17.7873
KYSE-140 CTRP2 3.9493 6.3559 3.6659 14.9626
OE21 CTRP2 4.1297 5.4819 4.0771 12.9349
TE-6 CTRP2 4.3201 5.5084 4.2772 11.6332
KYSE-410 CTRP2 4.3411 5.743 4.2583 11.6324
KYSE-70 CTRP2 4.4512 6.0244 4.3111 11.1038
TE-14 CTRP2 4.4545 5.8963 4.3474 10.9634
COLO 680N CTRP2 4.5345 5.2826 4.5266 10.0856
KYSE-30 CTRP2 4.5647 5.1189 4.5633 9.8626
TE-5 CTRP2 4.7792 5.9211 4.6953 8.7196
KYSE-510 CTRP2 4.9136 5.8816 4.8507 7.7504
TE-11 CTRP2 5.1884 9.2289 3.6926 11.6665
KYSE-150 CTRP2 5.3283 5.8736 5.3021 4.8603
EC-GI-10 CTRP2 5.5267 6.1328 5.453 3.7109
OE33 CTRP2 5.548 8.7376 4.2646 8.4975
TE-9 CTRP2 5.6576 8.098 4.6797 6.5291
TE-10 CTRP2 5.9875 8.5033 4.7672 5.4792
KYSE-520 CTRP2 6.8442 8.9945 5.1708 2.3848
TE-1 CTRP2 7.5116 11.9656 4.1992 5.3353
KYSE-450 CTRP2 7.5497 11.0192 4.6716 3.4294
KYSE-180 CTRP2 9.2832 21.5712 0.7865 15.1781
OE19 CTRP2 11.6311 24.7192 0.8508 11.8787
⏷ Show the Full List of 24 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 36 Cell Line(s) in Pancreas Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
N2a-PK1 CTRP2 9.1526 14.9959 3.8169 4.7749
HPAC CTRP2 3.3274 4.9696 3.289 18.2306
Panc 10.05 CTRP2 3.6596 5.743 3.5175 16.3787
SU.86.86 CTRP2 4.0068 4.9179 4.0008 13.5946
BxPC-3 CTRP2 4.2761 5.7062 4.1953 12.0579
Capan-2 CTRP2 4.2941 5.8645 4.1802 12.0549
Hs 766T CTRP2 4.2979 5.5563 4.246 11.812
SNU-213 CTRP2 4.31 5.6866 4.2359 11.8087
HuP-T4 CTRP2 4.4079 6.382 4.156 11.8001
KP-3 CTRP2 4.4786 5.9431 4.3622 10.8363
PaTu 8902 CTRP2 4.5177 4.9877 4.5173 10.1723
PK-59 CTRP2 4.5428 9.1708 3.1035 15.5788
CFPAC-1 CTRP2 4.5474 5.6596 4.4973 10.1442
Panc 08.13 CTRP2 4.558 5.6085 4.5171 10.0415
QGP-1 CTRP2 4.566 10.4593 2.5098 17.8657
MIA PaCa-2 CTRP2 4.7638 5.9566 4.6698 8.8579
TCC-Pan2 CTRP2 4.937 6.8457 4.5513 8.8039
KP-4 CTRP2 5.0123 5.9102 4.9517 7.0852
PaTu 8988s CTRP2 5.0236 6.4006 4.8161 7.5488
SUIT-2 CTRP2 5.0643 5.9238 5.0051 6.7342
HuP-T3 CTRP2 5.2598 7.0341 4.8047 6.9539
Panc 03.27 CTRP2 5.2682 6.922 4.863 6.7005
AsPC-1 CTRP2 5.3777 6.529 5.1445 5.304
SW1990 CTRP2 5.4163 6.5818 5.163 5.1282
KP-2 CTRP2 5.4344 5.956 5.4006 4.1806
PSN1 CTRP2 5.4532 6.169 5.3614 4.266
Panc 04.03 CTRP2 5.4658 5.9808 5.4291 3.9816
Panc 02.03 CTRP2 5.5129 6.029 5.4685 3.6957
Capan-1 CTRP2 5.5451 6.1993 5.4506 3.6662
PANC-1 CTRP2 5.5703 6.1454 5.4963 3.4225
PaTu 8988t CTRP2 5.6433 6.0646 5.601 2.8206
Panc 05.04 CTRP2 7.0172 11.6624 3.9991 6.8843
HPAF-II CTRP2 7.9951 16.8703 2.1586 12.5306
YAPC CTRP2 7.9995 9.3278 5.6136 0.1556
L3.3 CTRP2 8.4493 14.8558 3.4456 7.0108
DAN-G CTRP2 10.0768 47.7008 -11.5261 33.9938
⏷ Show the Full List of 36 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 48 Cell Line(s) in Skin Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
SH4 CTRP2 0.8277 4.5464 0.6792 35.2253
A101D CTRP2 2.5169 3.0457 2.5169 23.5005
UACC-257 CTRP2 2.5546 2.9342 2.5546 23.2494
Mel Ho CTRP2 2.5697 4.1114 2.5598 23.1819
SK-MEL-24 CTRP2 2.6289 3.5978 2.6286 22.7555
WM115 CTRP2 2.6337 3.0279 2.6337 22.7228
COLO 792 CTRP2 2.6345 3.7087 2.6336 22.7205
IGR-1 CTRP2 2.645 4.1497 2.6355 22.679
SK-MEL-3 CTRP2 2.6482 4.0207 2.6427 22.6443
Hs 940.T CTRP2 2.8019 4.6328 2.7686 21.714
RVH-421 CTRP2 2.8591 4.9493 2.7944 21.44
RPMI-7951 CTRP2 3.2708 4.7295 3.2507 18.5455
G-361 CTRP2 3.3322 4.7083 3.3159 18.1237
MeWo CTRP2 3.8312 5.2484 3.7908 14.8812
IGR-37 CTRP2 3.9194 4.9547 3.9092 14.1911
Hs 934.T CTRP2 3.9322 5.4568 3.8691 14.2866
WM983B CTRP2 3.9974 5.8336 3.8643 14.0985
COLO 800 CTRP2 4.0544 5.5413 3.9864 13.49
HT-144 CTRP2 4.1107 5.321 4.0787 12.9905
Hs 294T CTRP2 4.2049 5.7479 4.1094 12.5838
SK-MEL-1 CTRP2 4.2431 5.0041 4.2393 12.0133
COLO 829 CTRP2 4.2626 8.0598 3.3321 15.3771
A2058 CTRP2 4.2686 4.9548 4.2665 11.8375
Hs 688(A).T CTRP2 4.3303 5.0994 4.3251 11.4371
WM266-4 CTRP2 4.3413 5.5707 4.2904 11.5196
SK-MEL-30 CTRP2 4.3628 4.9178 4.3622 11.205
Hs 944.T CTRP2 4.3802 5.4913 4.3439 11.2099
SK-MEL-5 CTRP2 4.4548 4.9978 4.454 10.5927
Mel JuSo CTRP2 4.4822 10.8046 2.2634 19.0112
SK-MEL-28 CTRP2 4.5469 5.003 4.5466 9.9778
IPC-298 CTRP2 4.5495 4.9785 4.5493 9.9598
WM88 CTRP2 4.5829 5.8312 4.5021 10.0155
WM1799 CTRP2 4.6202 6.8581 4.2113 10.986
UACC-62 CTRP2 4.7079 5.5376 4.6866 8.976
Hs 895.T CTRP2 5.1788 6.1226 5.0772 6.1251
K029AX CTRP2 5.1988 6.5783 4.9359 6.6004
SK-MEL-2 CTRP2 5.2275 9.436 3.6276 11.846
WT2-iPS CTRP2 5.2383 6.2101 5.1144 5.812
IGR-39 CTRP2 5.2689 5.8614 5.2401 5.265
HMCB CTRP2 5.3434 5.8394 5.324 4.7364
Hs 839.T CTRP2 5.3459 5.9358 5.3088 4.7812
CJM [Human melanoma] CTRP2 5.5884 6.0188 5.5535 3.159
LOX-IMVI CTRP2 5.877 7.5335 5.1561 4.0699
A-375 CTRP2 6.0293 8.1956 4.9562 4.6032
SK-MEL-31 CTRP2 6.1235 10.7735 3.7455 9.5001
MDA-MB-435S CTRP2 6.5316 11.3014 3.8101 8.4809
WM793 CTRP2 8.6263 14.9143 3.5322 6.4514
Hs 936.T CTRP2 13.0162 24.762 1.6588 7.973
⏷ Show the Full List of 48 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Ascites Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
COLO 684 CTRP2 5.2718 6.9841 4.8392 6.7856
Cancer Drug Sensitivity Data Curated from 12 Cell Line(s) in Autonomic Ganglia Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
SK-N-FI CTRP2 2.7604 4.613 2.7267 21.9918
SiMa CTRP2 3.6613 6.0671 3.4375 16.66
CHP-212 CTRP2 4.191 5.7764 4.0881 12.7025
Kelly CTRP2 4.3027 8.4668 3.1911 15.8302
SK-N-BE(2) CTRP2 4.3531 5.5455 4.307 11.4244
KP-N-SI9s CTRP2 4.4399 7.3042 3.8402 12.9146
CHP-126 CTRP2 4.4578 5.3318 4.4434 10.6185
SK-N-AS CTRP2 4.5423 6.2018 4.3596 10.6524
SK-N-SH CTRP2 4.594 6.2128 4.4125 10.3043
NH-6 CTRP2 4.6038 6.1078 4.4545 10.122
NB1 CTRP2 4.6766 7.4575 4.021 11.5758
IMR-32 CTRP2 4.892 12.1563 1.9819 19.108
⏷ Show the Full List of 12 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 7 Cell Line(s) in Biliary Tract Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
SNU-1079 CTRP2 3.0838 4.7227 3.0561 19.8169
HuCC-T1 CTRP2 4.1038 5.4228 4.0582 13.083
HuH-28 CTRP2 4.274 5.4751 4.2328 11.9345
SNU-478 CTRP2 4.3316 6.3517 4.0831 12.2945
SNU-1196 CTRP2 4.5011 5.229 4.4949 10.3025
SNU-869 CTRP2 5.4216 9.8854 3.583 11.6033
SNU-308 CTRP2 5.9382 10.0593 3.9478 9.0152
⏷ Show the Full List of 7 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 15 Cell Line(s) in Bone Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
MHH-ES-1 CTRP2 4.073 5.554 4.0043 13.3684
A-673 CTRP2 4.1299 5.1963 4.1114 12.8168
Hs 822.T CTRP2 4.2037 5.0845 4.1957 12.2897
SK-N-MC CTRP2 4.2134 4.9435 4.2107 12.2073
Hs 888.T CTRP2 4.2812 5.1256 4.2735 11.7725
SK-ES-1 CTRP2 4.3897 5.1789 4.3826 11.0476
SaOS-2 CTRP2 4.4344 5.4773 4.4035 10.8305
MG-63 CTRP2 4.6113 5.9418 4.5072 9.9089
SJSA-1 CTRP2 4.684 5.6973 4.6381 9.2199
CAL-78 CTRP2 5.0982 6.2288 4.9561 6.8096
TC71 CTRP2 5.1073 6.0053 5.0322 6.5048
G-292 clone A141B1 CTRP2 5.2859 8.1812 4.2928 8.9702
HOS CTRP2 5.4283 8.3748 4.3329 8.4782
SW1353 CTRP2 6.4652 11.2505 3.7832 8.7106
U2OS CTRP2 7.5274 12.1173 4.1372 5.5604
⏷ Show the Full List of 15 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 66 Cell Line(s) in Breast Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
DU4475 CTRP2 2.4867 3.0028 2.4867 23.7021
CAL-85-1 CTRP2 2.9257 4.4064 2.9127 20.8206
MDA-MB-468 CTRP2 3.1158 4.3203 3.1106 19.5279
HCC2218 CTRP2 3.7951 5.6161 3.692 15.3391
HCC1500 CTRP2 4.0216 6.0679 3.8304 14.1457
KPL-1 CTRP2 4.0823 4.8141 4.0804 15.1094
HCC1395 CTRP2 4.0846 5.3729 4.0446 13.1918
MCF-7 CTRP2 4.2031 8.2444 3.1896 16.0927
SK-BR-3 CTRP2 4.2258 5.6143 4.1584 12.3461
HCC1806 CTRP2 4.2266 8.2807 3.1975 16.0009
MDA-MB-453 CTRP2 4.2831 5.2286 4.269 11.7815
HMC-1-8 CTRP2 4.3075 4.8907 4.3068 11.5739
CAL-120 CTRP2 4.3273 4.9507 4.326 11.4437
T-47D CTRP2 4.4139 5.477 4.3817 10.9714
JIMT-1 CTRP2 4.4516 4.9593 4.4511 10.6129
MDA-MB-361 CTRP2 4.5136 5.8188 4.4295 10.4882
HDQ-P1 CTRP2 4.5566 5.1855 4.5534 9.9225
BT-474 CTRP2 4.5571 5.0482 4.5565 9.9107
HCC1143 CTRP2 4.6912 9.6022 3.0418 15.4681
MDA-MB-231 CTRP2 4.9559 8.7687 3.695 12.1947
ZR-75-1 CTRP2 4.9628 6.786 4.6028 8.534
HCC1428 CTRP2 5.0625 5.982 4.9892 6.7963
ZR-75-30 CTRP2 5.1893 6.2247 5.0564 6.1707
EFM-192A CTRP2 5.3292 6.2964 5.183 5.2917
HCC1954 CTRP2 5.3374 9.4394 3.7269 11.1916
HCC1419 CTRP2 5.3891 6.2333 5.27 4.7928
BT-20 CTRP2 5.427 6.2685 5.2985 4.577
CAL-51 CTRP2 5.535 7.0183 5.0875 5.1268
HCC38 CTRP2 5.9986 7.4074 5.3244 3.1161
BT-549 CTRP2 6.2178 7.5069 5.4522 2.1742
CAMA-1 CTRP2 6.8136 10.3727 4.483 5.2186
HCC1937 CTRP2 8.1589 14.5226 3.4117 7.5366
BT 248 CTRP2 2.6319 3.7887 2.6302 22.7402
BT 131 CTRP2 2.7036 4.1468 2.6955 22.2837
BT 428 CTRP2 2.7982 3.6314 2.7981 21.6269
BT 239 CTRP2 2.8711 4.0078 2.8688 21.1486
BT 231 CTRP2 2.9072 4.7539 2.8679 21.0328
BT 216 CTRP2 2.9096 3.9112 2.9087 20.8875
BT 271 CTRP2 2.9625 4.11 2.9597 20.5413
BT 228 CTRP2 2.9728 4.2488 2.967 20.4829
BT 286 CTRP2 3.0052 3.8141 3.005 20.2483
BT 422 CTRP2 3.0816 4.1151 3.0799 19.7442
BT 440 CTRP2 3.1349 4.5364 3.1217 19.4278
BT 245 CTRP2 3.1542 4.5607 3.1403 19.3016
BT 359 CTRP2 3.1623 4.369 3.1566 19.2198
BT147 CTRP2 3.189 4.2259 3.1868 19.0301
BT 232 CTRP2 3.2223 4.2958 3.2193 18.8112
BT 172 CTRP2 3.3344 4.1652 3.3338 18.0564
BT 187 CTRP2 3.4386 4.7505 3.4235 17.4108
BT 159 CTRP2 3.4721 4.6788 3.462 17.1706
BT 340 CTRP2 3.5365 4.358 3.5356 16.7108
BT 416 CTRP2 3.7592 5.3687 3.6972 15.4352
BT 333 CTRP2 3.7979 4.997 3.7804 15.0254
BT 482 CTRP2 3.966 5.0139 3.9539 13.8871
BT 320 CTRP2 4.0652 4.9689 4.0586 13.2079
BT 330 CTRP2 4.123 4.8831 4.1203 12.8098
BT 139 CTRP2 4.1438 5.2827 4.1179 12.7493
BT 504 CTRP2 4.2476 5.527 4.1967 12.1439
BT 444 CTRP2 4.3218 5.101 4.3164 11.4942
BT 498 CTRP2 4.4301 5.753 4.3528 11.0204
BT 112 CTRP2 4.4551 5.7971 4.3707 10.8788
BT 328 CTRP2 4.5302 5.0241 4.5297 10.0895
BT 145 CTRP2 4.895 6.3871 4.6822 8.4218
BT164 CTRP2 5.2314 6.0891 5.1446 5.7216
BT 179 CTRP2 5.391 5.895 5.3658 4.4393
BT 224 CTRP2 5.5873 7.6656 4.8272 6.0726
⏷ Show the Full List of 66 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Tongue Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
YD-38 CTRP2 4.5396 6.3389 4.3132 10.8314
Cancer Drug Sensitivity Data Curated from 46 Cell Line(s) in Central Nervous System Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
Hs 683 CTRP2 2.8656 3.5689 2.8655 21.1779
SF268 CTRP2 3.7195 5.3688 3.6546 15.7098
CAS-1 CTRP2 3.7198 4.2298 3.7198 17.8923
SNB-75 CTRP2 3.7251 5.3958 3.6563 15.6856
KG-1-C CTRP2 3.9468 5.1726 3.9214 14.0603
LN-18 CTRP2 4.0257 4.7504 4.0242 13.4539
SNU-466 CTRP2 4.1128 5.1978 4.0934 12.9341
A-172 CTRP2 4.1704 5.8859 4.0403 12.9361
SF539 CTRP2 4.1933 5.3098 4.1674 12.4196
LN-229 CTRP2 4.2102 5.1713 4.1972 12.2633
KNS-81 CTRP2 4.3505 5.0554 4.3472 11.2959
U-251MG CTRP2 4.3711 5.3986 4.3457 11.2333
Daoy CTRP2 4.3807 5.4791 4.3461 11.2012
NMC-G1 CTRP2 4.3932 5.1802 4.3861 11.0245
GB-1 CTRP2 4.414 5.276 4.4018 10.9029
42-MG-BA CTRP2 4.4477 5.7211 4.3783 10.8752
SNU-1105 CTRP2 4.4791 9.269 2.995 16.1671
KNS-60 CTRP2 4.5118 4.9321 4.5117 10.2105
DBTRG-05MG CTRP2 4.5271 10.9573 2.2318 19.0234
D283 Med CTRP2 4.5684 6.0152 4.4415 10.2764
ONS-76 CTRP2 4.5857 5.4037 4.5712 9.7665
AM-38 CTRP2 4.6035 5.5515 4.5739 9.6998
GaMG CTRP2 4.6884 5.9524 4.5887 9.3804
SNU-626 CTRP2 4.7976 5.5248 4.7827 8.3564
SW1783 CTRP2 4.9475 6.2339 4.7907 7.8647
SW1088 CTRP2 5.088 6.2775 4.9288 6.9409
SNU-201 CTRP2 5.0885 6.1912 4.9576 6.8326
U-118MG CTRP2 5.1031 10.1886 3.1436 14.1048
M059K CTRP2 5.139 6.7192 4.8155 7.2295
SF126 CTRP2 5.182 7.571 4.4813 8.4491
TM-31 CTRP2 5.238 5.9187 5.1952 5.5195
GOS-3 CTRP2 5.2557 6.2381 5.124 5.7254
SNU-738 CTRP2 5.2591 5.983 5.2033 5.4256
SNU-489 CTRP2 5.2775 6.4085 5.0859 5.8063
Becker CTRP2 5.3204 8.881 3.9852 10.1607
T98G CTRP2 5.3743 10.1489 3.41 12.4186
GMS-10 CTRP2 5.4004 5.8536 5.383 4.3496
DK-MG CTRP2 5.4136 5.942 5.381 4.3149
KNS-42 CTRP2 5.4369 5.9257 5.4096 4.1411
8-MG-BA CTRP2 5.5393 6.0086 5.5026 3.4925
YKG-1 CTRP2 5.543 5.9312 5.5234 3.4073
YH-13 CTRP2 5.5438 6.0453 5.4978 3.4961
CCF-STTG1 CTRP2 6.0239 6.6689 5.7149 1.4249
SF295 CTRP2 7.1099 9.9681 4.8836 3.165
U-87MG ATCC CTRP2 7.9262 12.5354 4.2011 4.7752
KALS-1 CTRP2 9.1323 21.0767 0.9203 14.9842
⏷ Show the Full List of 46 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 21 Cell Line(s) in Endometrium Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
JHUEM-2 CTRP2 3.6271 5.0715 3.5946 16.2139
HEC-1-A CTRP2 3.8662 5.2332 3.8297 14.635
HEC-1-B CTRP2 4.3479 9.4677 2.7731 17.3668
RL95-2 CTRP2 4.415 7.8374 3.5861 13.9775
MFE-296 CTRP2 4.4535 5.8912 4.3475 10.9663
JHUEM-7 CTRP2 4.744 5.5773 4.7201 8.7443
JHUEM-3 CTRP2 4.7506 6.1992 4.5874 9.1966
HEC-151 CTRP2 5.1062 5.9478 5.0452 6.4618
JHUEM-1 CTRP2 5.1651 6.3914 4.9718 6.5575
EN CTRP2 5.1952 6.2227 5.0635 6.1268
EFE-184 CTRP2 5.294 6.0742 5.2171 5.2692
AN3-CA CTRP2 5.3538 7.8867 4.4992 7.9634
MFE-319 CTRP2 5.4179 5.9821 5.3766 4.317
ESS-1 CTRP2 5.503 6.0244 5.4589 3.7607
HEC-50B CTRP2 6.1678 8.0605 5.1373 3.5814
HEC-59 CTRP2 6.2482 9.2699 4.5982 5.6966
HEC-265 CTRP2 6.5361 12.1329 3.3996 10.165
HEC-6 CTRP2 7.0418 11.2877 4.2003 6.0221
HEC-108 CTRP2 9.2557 17.6919 2.6302 8.9862
HEC-251 CTRP2 9.6449 20.3061 1.645 11.898
Ishikawa (Heraklio) 02 ER- CTRP2 6.7716 9.6869 4.7879 4.0322
⏷ Show the Full List of 21 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 20 Cell Line(s) in Kidney Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
KMRC-3 CTRP2 3.0824 4.7039 3.0562 19.821
UO-31 CTRP2 3.5298 5.3513 3.4535 17.0126
BFTC-909 CTRP2 4.1951 5.7994 4.0875 12.6918
TUHR14TKB CTRP2 4.3222 5.6033 4.2644 11.6708
KMRC-20 CTRP2 4.3748 5.1487 4.3687 11.1435
VMRC-RCW CTRP2 4.3864 6.8941 3.9484 12.6441
TUHR4TKB CTRP2 4.5297 5.079 4.5285 10.0951
TUHR10TKB CTRP2 4.6289 5.09 4.6284 9.4316
RCC10RGB CTRP2 5.0015 6.1251 4.8832 7.3648
CAL-54 CTRP2 5.0435 6.3815 4.8445 7.385
VMRC-RCZ CTRP2 5.2453 7.8755 4.4001 8.6261
KMRC-2 CTRP2 5.314 5.9027 5.281 4.9793
786-O CTRP2 5.3207 6.513 5.0909 5.6672
Caki-1 CTRP2 5.4112 7.6029 4.6902 7.045
KMRC-1 CTRP2 5.4411 5.9438 5.4105 4.1247
ACHN CTRP2 5.4624 5.9824 5.4251 4.0065
Caki-2 CTRP2 5.4716 5.888 5.454 3.8763
OS-RC-2 CTRP2 6.7913 10.5961 4.357 5.7734
SNU-1272 CTRP2 7.375 11.369 4.3927 4.7538
769-P CTRP2 9.4335 17.1189 3.0123 7.3759
⏷ Show the Full List of 20 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 44 Cell Line(s) in Large Intestine Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
SNU-81 CTRP2 2.9553 6.3043 2.5988 21.8327
HT115 CTRP2 3.1904 4.2203 3.1883 19.0207
T84 CTRP2 3.2842 4.8007 3.2594 18.4723
SW48 CTRP2 3.4084 6.1783 3.13 18.5395
COLO 320 CTRP2 3.4166 7.5636 2.6551 20.2799
NCI-H747 CTRP2 3.4505 5.2362 3.3863 17.4987
SNU-1033 CTRP2 3.5232 5.5313 3.4142 17.1705
LS1034 CTRP2 3.5829 5.8623 3.4056 17.0147
OUMS-23 CTRP2 3.7243 5.1723 3.6865 15.5845
SNU-C1 CTRP2 3.9447 5.7294 3.8307 14.3816
LS513 CTRP2 4.0882 5.4123 4.0431 13.1854
HT-29 CTRP2 4.1414 5.0388 4.1337 12.7039
LoVo CTRP2 4.2655 8.2001 3.273 15.6024
SK-CO-1 CTRP2 4.3013 5.1983 4.29 11.6507
CL-11 CTRP2 4.3326 6.1507 4.1462 12.0603
LS180 CTRP2 4.354 5.9294 4.2297 11.6936
COLO201 CTRP2 4.462 7.8235 3.6403 13.6409
C2BBe1 CTRP2 4.4879 5.8111 4.4033 10.6611
SNU-407 CTRP2 4.5241 6.4042 4.2747 11.0192
RKO CTRP2 4.5456 5.9004 4.4457 10.3314
SNU-C2A CTRP2 4.5766 10.5559 2.473 17.983
KM12 CTRP2 4.7138 5.6888 4.6716 9.0084
LS411N CTRP2 4.8553 5.5997 4.8357 7.9882
DLD-1 CTRP2 4.8575 5.5986 4.8381 7.9726
HCT 15 CTRP2 4.8747 6.0149 4.7758 8.1378
HCT 8 CTRP2 4.8827 5.5679 4.868 7.7892
SNU-C4 CTRP2 5.0026 5.8633 4.9513 7.117
SNU-61 CTRP2 5.0218 8.7234 3.78 11.692
HT-55 CTRP2 5.1909 8.1544 4.2147 9.5135
SNU-C5 CTRP2 5.2709 6.1692 5.1631 5.536
SNU-503 CTRP2 5.2849 7.449 4.6398 7.5543
COLO 678 CTRP2 5.3639 6.3335 5.2067 5.1034
SW948 CTRP2 5.4422 6.1441 5.3575 4.3124
RCM-1 [Human ESC] CTRP2 5.4572 6.1921 5.358 4.2668
SW1417 CTRP2 5.4872 6.1596 5.4013 4.0183
HCT 116 CTRP2 5.7016 8.4024 4.5688 6.8976
HCC-56 CTRP2 5.8421 6.3967 5.6804 1.9711
GP2d CTRP2 5.9685 6.9224 5.5406 2.2687
NCI-H716 CTRP2 6.0626 7.9799 5.0918 3.9689
SW620 CTRP2 7.222 10.548 4.6822 3.8117
LS123 CTRP2 7.2877 9.5738 5.1766 1.8329
CW-2 CTRP2 7.3224 11.6886 4.2033 5.5884
MDST8 CTRP2 7.7548 8.9972 5.6389 0.1787
COLO205 CTRP2 7.8073 12.5286 4.1275 5.2167
⏷ Show the Full List of 44 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 22 Cell Line(s) in Liver Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
SNU-182 CTRP2 2.6551 4.6903 2.6086 22.7366
SNU-761 CTRP2 3.3575 5.0927 3.3066 18.073
HuH-6 CTRP2 3.5631 5.5174 3.46 16.884
Li-7 CTRP2 3.8909 6.0506 3.6925 15.041
Hep-G2 CTRP2 4.1658 5.924 4.0259 13.0019
SNU-878 CTRP2 4.187 5.6359 4.1125 12.6292
Hep 3B2.1-7 CTRP2 4.365 8.9106 3.0501 16.2313
SNU-886 CTRP2 4.5082 6.8051 4.1125 11.6764
JHH-1 CTRP2 4.5453 5.5904 4.5062 10.12
HLF CTRP2 4.6516 5.951 4.5489 9.6358
SNU-387 CTRP2 4.7008 6.5912 4.3994 10.0428
HuH-1 CTRP2 4.9912 5.9029 4.9303 7.2269
JHH-4 CTRP2 5.0998 6.1152 4.9934 6.6679
JHH-5 CTRP2 5.1462 6.6204 4.8633 7.0247
PLC/PRF/5 CTRP2 5.1997 6.503 4.9666 6.4796
JHH-2 CTRP2 5.2365 7.8337 4.4115 8.6006
SK-HEP-1 CTRP2 5.4531 5.9254 5.4273 4.0277
SNU-475 CTRP2 5.5144 5.9515 5.4884 3.6203
SNU-423 CTRP2 5.5218 6.1023 5.4572 3.7099
JHH-6 CTRP2 5.6417 5.964 5.624 2.7433
SNU-449 CTRP2 6.1172 13.8547 2.1998 15.6987
SNU-398 CTRP2 7.1117 10.0459 4.8479 3.3035
⏷ Show the Full List of 22 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 137 Cell Line(s) in Lung Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
NCI-H810 CTRP2 2.5421 3.1107 2.5421 23.3327
NCI-H2081 CTRP2 2.5529 4.1168 2.5424 23.2961
NCI-H2171 CTRP2 2.6879 4.184 2.6781 22.3941
NCI-H211 CTRP2 2.9153 3.9744 2.9138 20.8514
DMS 454 CTRP2 2.9224 4.8652 2.8721 20.9689
NCI-H1105 CTRP2 2.9343 5.1136 2.8516 21.0014
Calu-3 CTRP2 3.0571 3.9516 3.0566 19.9032
HCC2935 CTRP2 3.1982 5.9598 2.961 19.7885
HCC95 CTRP2 3.298 4.4414 3.2927 18.3144
NCI-H1666 CTRP2 3.3216 5.6126 3.1788 18.6315
NCI-H1694 CTRP2 3.4287 5.0733 3.3845 17.5755
NCI-H2087 CTRP2 3.4578 6.5111 3.0817 18.5684
NCI-H69 CTRP2 3.4747 5.2998 3.4026 17.3648
NCI-H1693 CTRP2 3.4982 5.5659 3.3802 17.3686
EKVX CTRP2 3.5521 6.3044 3.2493 17.6731
HCC44 CTRP2 3.6582 6.2623 3.3776 16.8867
DMS 53 CTRP2 3.7671 5.1967 3.7289 15.3009
SK-MES-1 CTRP2 3.7783 5.4823 3.699 15.3682
NCI-H1385 CTRP2 3.7832 5.0512 3.7607 15.1401
NCI-H520 CTRP2 3.8223 5.7514 3.6927 15.2516
SW1271 CTRP2 3.8682 5.5342 3.7868 14.7764
NCI-H1734 CTRP2 3.89 5.5652 3.8046 14.6454
NCI-H1581 CTRP2 3.9663 5.2799 3.9304 13.966
NCI-H661 CTRP2 3.9965 6.3675 3.7136 14.6472
HOP-92 CTRP2 4.02 5.6292 3.9331 13.7848
NCI-H1184 CTRP2 4.0341 8.4754 2.9148 17.6093
HCC2279 CTRP2 4.0411 5.9825 3.8747 13.9268
LCLC-97TM1 CTRP2 4.0444 6.2569 3.8002 14.1869
HCC1588 CTRP2 4.0529 5.3264 4.0168 13.3896
NCI-H2106 CTRP2 4.0821 5.4728 4.0275 13.2591
NCI-H1568 CTRP2 4.0832 5.5429 4.0172 13.291
NCI-H1355 CTRP2 4.0881 5.8043 3.9699 13.4415
NCI-H1092 CTRP2 4.0932 5.9217 3.9472 13.5066
NCI-H1341 CTRP2 4.128 5.2483 4.1048 12.8454
NCI-H2141 CTRP2 4.1319 6.2647 3.8931 13.5857
HCC1171 CTRP2 4.1584 5.9029 4.023 13.0349
NCI-H1793 CTRP2 4.2047 5.5712 4.1432 12.4662
BEN CTRP2 4.2447 4.8306 4.2441 11.9919
MOR/CPR CTRP2 4.2622 4.8218 4.2617 11.875
NCI-H446 CTRP2 4.297 5.4832 4.2562 11.7799
HCC1833 CTRP2 4.3204 5.4178 4.2897 11.5894
HOP-62 CTRP2 4.3276 5.6917 4.254 11.6899
NCI-H1155 CTRP2 4.3309 5.6872 4.2584 11.6643
NCI-H1435 CTRP2 4.3339 9.1938 2.8877 16.951
LXF 289 CTRP2 4.338 7.3106 3.7307 13.6158
RERF-LC-A1 CTRP2 4.3411 5.5199 4.298 11.4941
NCI-H526 CTRP2 4.3513 5.1511 4.3445 11.3024
NCI-H2009 CTRP2 4.3527 5.457 4.3191 11.384
HARA [Human squamous cell lung carcinoma] CTRP2 4.3765 5.6721 4.3106 11.3375
EBC-1 CTRP2 4.3974 5.311 4.3819 11.0247
NCI-H2085 CTRP2 4.4116 7.1298 3.882 12.8296
COLO 668 CTRP2 4.4153 6.3544 4.1732 11.7148
NCI-H2023 CTRP2 4.4234 7.7407 3.6371 13.7544
NCI-H1573 CTRP2 4.4267 5.8479 4.3285 11.1168
NCI-H841 CTRP2 4.4357 7.1253 3.9092 12.6582
NCI-H1373 CTRP2 4.4401 7.592 3.7186 13.3896
NCI-H727 CTRP2 4.4456 5.6046 4.397 10.8171
NCI-H1944 CTRP2 4.4787 5.8082 4.394 10.7228
SHP-77 CTRP2 4.4823 5.081 4.4805 10.4131
NCI-H2126 CTRP2 4.4982 8.9142 3.1802 15.3819
NCI-H889 CTRP2 4.5231 6.0406 4.3852 10.6171
NCI-H1650 CTRP2 4.5331 5.7384 4.4674 10.2939
NCI-H1651 CTRP2 4.5365 6.8813 4.1132 11.595
NCI-H522 CTRP2 4.5382 5.6389 4.4909 10.1959
CAL-12T CTRP2 4.5477 5.3545 4.5354 10.0125
Lu-65 CTRP2 4.552 6.1113 4.397 10.487
NCI-H2228 CTRP2 4.5595 5.6097 4.5185 10.0323
NCI-H1838 CTRP2 4.5647 5.1812 4.5618 9.8677
Lu-99 CTRP2 4.5679 5.3614 4.556 9.8769
HCC366 CTRP2 4.5855 5.8275 4.5057 9.9945
PC-14 CTRP2 4.6025 5.6177 4.5635 9.7387
NCI-H2444 CTRP2 4.6115 5.177 4.6096 9.5526
NCI-H2172 CTRP2 4.6127 8.486 3.4926 13.8469
NCI-H358 CTRP2 4.6148 5.8783 4.5262 9.8308
HCC15 CTRP2 4.6202 6.5595 4.3242 10.5564
DV-90 CTRP2 4.6327 6.3099 4.4239 10.1478
EPLC-272H CTRP2 4.6475 7.089 4.147 11.1598
DMS 273 CTRP2 4.6739 6.2642 4.4834 9.8069
Calu-1 CTRP2 4.6747 5.3159 4.6694 9.1427
NCI-H292 CTRP2 4.6846 5.8691 4.6044 9.3361
NCI-H1915 CTRP2 4.7318 6.1074 4.5942 9.2281
NCI-H322 CTRP2 4.7327 6.3546 4.5176 9.5075
NCI-H1792 CTRP2 4.7388 6.6246 4.4277 9.828
NCI-H2405 CTRP2 4.7601 8.1516 3.7937 12.2699
DMS 114 CTRP2 4.7648 6.1821 4.608 9.0788
NCI-H1703 CTRP2 4.8033 6.7232 4.4589 9.5279
NCI-H2342 CTRP2 4.8477 6.8229 4.4664 9.3763
LOU-NH91 CTRP2 4.8596 5.5558 4.8449 7.9431
NCI-H1563 CTRP2 4.902 6.2375 4.74 8.1861
NCI-H2196 CTRP2 4.9478 6.5164 4.6922 8.233
HCC1438 CTRP2 4.9969 6.0224 4.9071 7.2921
VMRC-LCD CTRP2 5.0128 6.4098 4.8013 7.6356
ChaGo-K-1 CTRP2 5.0184 6.0852 4.9133 7.2043
LCLC-103H CTRP2 5.0273 9.1885 3.561 12.5755
COR-L95 CTRP2 5.0382 6.396 4.8336 7.441
NCI-H2029 CTRP2 5.0655 6.1226 4.9538 6.915
NCI-H23 CTRP2 5.0753 8.0675 4.1438 10.0793
RERF-LC-MS CTRP2 5.1959 7.9083 4.3366 9.0034
NCI-H647 CTRP2 5.199 6.8049 4.8424 6.9635
NCI-H650 CTRP2 5.2004 13.5954 1.5443 19.9931
NCI-H226 CTRP2 5.2203 6.0781 5.1356 5.7875
LC-1F CTRP2 5.2212 8.1287 4.2561 9.2723
COR-L105 CTRP2 5.2801 7.5502 4.5877 7.7777
COR-L51 CTRP2 5.2936 6.3018 5.1427 5.5458
KNS-62 CTRP2 5.3013 6.0254 5.2385 5.1696
NCI-H196 CTRP2 5.3016 6.2346 5.1748 5.4025
HCC78 CTRP2 5.3482 7.4519 4.7007 7.1529
NCI-H838 CTRP2 5.3557 5.9257 5.3215 4.7058
SBC-5 CTRP2 5.3575 5.9273 5.3232 4.6942
LC-1/sq-SF CTRP2 5.3713 6.1835 5.2676 4.8539
NCI-H2110 CTRP2 5.3802 6.6837 5.082 5.5418
NCI-H1395 CTRP2 5.3818 6.692 5.0802 5.5446
SK-LU-1 CTRP2 5.3862 8.8599 4.0564 9.7186
HCC4006 CTRP2 5.3989 6.0438 5.3401 4.506
T3M-10 CTRP2 5.4038 6.0231 5.351 4.452
NCI-H1339 CTRP2 5.445 5.9186 5.4198 4.0799
HCC1195 CTRP2 5.4863 5.9659 5.4548 3.8268
NCI-H2170 CTRP2 5.4881 5.9958 5.4499 3.8385
LUDLU-1 CTRP2 5.5099 6.0935 5.447 3.7827
NCI-H2291 CTRP2 5.5551 12.6724 2.3143 16.407
NCI-H441 CTRP2 5.5979 10.1401 3.6135 11.1015
NCI-H1299 CTRP2 5.6184 8.4281 4.4812 7.4417
NCI-H1869 CTRP2 5.702 7.5034 5.013 5.0446
A-549 CTRP2 5.854 7.6402 5.0828 4.425
NCI-H1755 CTRP2 6.296 9.1917 4.6752 5.2874
HCC827 CTRP2 6.3795 12.8194 2.932 12.3462
RERF-LC-Ad2 CTRP2 6.4687 7.7231 5.5269 1.4797
Calu-6 CTRP2 6.7953 11.4356 3.9461 7.4642
NCI-H460 CTRP2 6.9761 10.4007 4.5854 4.5504
NCI-H2030 CTRP2 7.271 11.4261 4.2945 5.2956
RERF-LC-Ad1 CTRP2 7.2746 8.48 5.6358 0.3689
NCI-H2286 CTRP2 7.7289 12.1964 4.2335 4.9046
NCI-H2122 CTRP2 8.2434 13.5824 3.9125 5.4857
HCC2108 CTRP2 8.6614 17.3992 2.3723 10.7424
COLO 699 CTRP2 9.5347 18.8634 2.2581 9.9446
LK2 CTRP2 9.7655 28.765 -2.3837 22.6081
Hs 888.Lu CTRP2 5.3318 6.0351 5.2692 4.9661
⏷ Show the Full List of 137 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Clivus Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
U-CH1 CTRP2 1.0016 2.3493 -2.3711 0.0715
Cancer Drug Sensitivity Data Curated from 40 Cell Line(s) in Ovary Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
2004 CTRP2 3.3353 5.1548 3.2748 18.2536
COV644 CTRP2 2.6115 14.6874 -1.3896 34.3683
COV434 CTRP2 3.1623 4.4549 3.1536 19.2297
A2780 CTRP2 3.814 5.8293 3.6655 15.3736
Caov-3 CTRP2 3.8381 5.5418 3.7529 14.9903
OVCAR-5 CTRP2 4.1023 5.656 4.017 13.2312
OVK18 CTRP2 4.1596 6.2689 3.922 13.3972
SNU-119 CTRP2 4.1651 5.3648 4.1312 12.6346
Kuramochi CTRP2 4.3525 5.9275 4.2285 11.7024
TYK-nu CTRP2 4.3828 5.403 4.3575 11.1552
OC 314 CTRP2 4.3984 4.9306 4.3979 10.9675
ONCO-DG-1 CTRP2 4.4782 5.5617 4.4386 10.5689
MCAS CTRP2 4.5348 5.7124 4.4742 10.2645
OVSAHO CTRP2 4.6248 10.4287 2.5802 17.4522
OAW28 CTRP2 4.7558 6.1819 4.5983 9.1412
COV362 CTRP2 4.7596 6.355 4.5467 9.3205
SNU-8 CTRP2 4.8668 5.5633 4.8517 7.8961
OVTOKO CTRP2 4.9244 7.3425 4.3258 9.7234
SNU-840 CTRP2 5.0262 5.831 4.9834 6.9299
OV7 CTRP2 5.1892 6.1171 5.0902 6.0465
OAW42 CTRP2 5.234 5.9958 5.1728 5.612
JHOS-2 CTRP2 5.2382 6.2006 5.1175 5.8006
TOV-112D CTRP2 5.3164 6.7473 4.9887 6.0774
OV-90 CTRP2 5.317 7.8802 4.4671 8.1815
IGROV-1 CTRP2 5.3747 8.5162 4.214 9.0915
OV56 CTRP2 5.3857 5.8497 5.3678 4.449
EFO-27 CTRP2 5.53 6.0383 5.4846 3.5856
FU-OV-1 CTRP2 5.5361 8.2848 4.4767 7.6409
EFO-21 CTRP2 5.5463 5.9949 5.5135 3.4318
TOV-21G CTRP2 5.5545 6.084 5.4984 3.4614
RMG-I CTRP2 5.6738 9.8815 3.8089 10.131
OVCAR-8 CTRP2 5.9142 9.2417 4.336 7.4357
JHOM-1 CTRP2 6.1117 7.1874 5.528 2.0441
DOV13 CTRP2 6.883 10.3545 4.542 4.8682
HEY A8 CTRP2 7.2554 14.3198 2.8675 11.0531
OVISE CTRP2 7.8266 12.0661 4.3575 4.2961
SK-OV-3 CTRP2 8.1132 13.3205 3.9522 5.4994
ES2 CTRP2 8.118 13.711 3.7709 6.1964
OVCAR-4 CTRP2 8.4507 10.2897 5.441 0.306
JHOC-5 CTRP2 8.4929 16.3961 2.7396 9.6297
⏷ Show the Full List of 40 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 22 Cell Line(s) in Soft Tissue Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
Aska-SS CTRP2 4.3517 5.505 4.3115 11.4136
Yamato-SS CTRP2 4.4128 5.051 4.4107 10.8768
TTC-709 CTRP2 3.5079 4.8131 3.4915 16.9532
Tm87-16 CTRP2 3.5397 5.1625 3.4916 16.8497
RD CTRP2 3.5705 6.1216 3.323 17.3495
Rh41 CTRP2 3.665 5.195 3.6207 16.0017
A-204 CTRP2 3.8305 5.1975 3.796 14.8656
TE 617.T CTRP2 4.0609 5.5579 3.9906 13.4546
TE 441.T CTRP2 4.212 6.4358 3.9256 13.2291
Rh18 CTRP2 4.2132 5.8668 4.0915 12.6215
GCT CTRP2 4.2318 5.4109 4.1963 12.1959
BT-16 CTRP2 4.2372 5.1197 4.2284 12.0691
KYM-1 CTRP2 4.3881 5.5817 4.3389 11.2018
SW982 CTRP2 4.5065 5.0338 4.5057 10.2486
G-401 CTRP2 4.6845 6.8232 4.2933 10.493
Hs 729.T CTRP2 5.0994 6.2333 4.9559 6.8069
G-402 CTRP2 5.1336 7.2208 4.5929 8.1218
MES-SA CTRP2 5.1849 7.7548 4.3983 8.7788
HT-1080 CTRP2 5.2568 6.1588 5.1512 5.6214
SK-UT-1 CTRP2 5.2627 9.2436 3.7543 11.2446
SK-LMS-1 CTRP2 5.3839 7.59 4.6701 7.1921
RKN CTRP2 7.2775 9.5291 5.1908 1.7921
⏷ Show the Full List of 22 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 2 Cell Line(s) in Thigh Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
H-STS CTRP2 5.7813 6.6373 5.5077 2.8209
SYO-1 CTRP2 9.1908 26.8671 -1.8752 22.3518
Cancer Drug Sensitivity Data Curated from 8 Cell Line(s) in Pleura Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
NCI-H2452 CTRP2 3.9594 6.1579 3.737 14.6726
MSTO-211H CTRP2 4.4102 5.4706 4.3786 10.9943
NCI-H28 CTRP2 4.57 6.4691 4.3022 10.7837
ACC-MESO-1 CTRP2 4.5979 5.3136 4.5903 9.6624
IST-Mes1 CTRP2 4.6089 6.6595 4.2754 10.7731
MPP 89 CTRP2 5.4881 6.2521 5.3702 4.1319
NCI-H2052 CTRP2 7.4407 10.7881 4.7107 3.4141
JL-1 CTRP2 7.5162 14.3297 3.0551 9.8923
⏷ Show the Full List of 8 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 5 Cell Line(s) in Prostate Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
22Rv1 CTRP2 4.7694 8.3279 3.7213 12.5386
VCaP CTRP2 5.1866 6.0894 5.0956 6.0348
LNCaP clone FGC CTRP2 5.4046 6.2339 5.2866 4.686
DU145 CTRP2 5.4493 7.7927 4.6355 7.1806
PaCa-3 CTRP2 5.6111 5.9344 5.5964 2.937
Cancer Drug Sensitivity Data Curated from 2 Cell Line(s) in Salivary Gland Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
YD-15 CTRP2 4.4398 7.5098 3.7534 13.2537
A-253 CTRP2 5.3488 6.5769 5.0945 5.5766
Cancer Drug Sensitivity Data Curated from 34 Cell Line(s) in Stomach Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
SNU-16 CTRP2 2.4374 3.0081 2.4374 24.0301
GSS CTRP2 2.7788 4.109 2.7733 21.7744
HGC-27 CTRP2 3.2691 4.6753 3.2526 18.5449
Fu97 CTRP2 3.2917 5.3638 3.195 18.6693
SNU-620 CTRP2 3.5355 4.8676 3.5164 16.7789
OCUM-1 CTRP2 3.5602 5.3664 3.4838 16.8106
ECC10 CTRP2 3.713 5.2675 3.6624 15.7037
KE-39 CTRP2 3.9371 6.0893 3.7322 14.7573
GSU CTRP2 4.0549 4.6842 4.0544 13.256
SNU-5 CTRP2 4.1491 6.3369 3.8893 13.5483
SNU-601 CTRP2 4.1964 5.1213 4.1861 12.346
HuG1-N CTRP2 4.2269 5.8051 4.1208 12.4749
NCI-N87 CTRP2 4.2918 7.2537 3.7054 13.8398
AGS CTRP2 4.3358 5.6258 4.2751 11.5902
NUGC-4 CTRP2 4.3872 5.4434 4.3576 11.1407
SNU-216 CTRP2 4.3989 5.9149 4.2822 11.3676
23132/87 CTRP2 4.4104 5.2242 4.4015 10.9155
IM95 CTRP2 4.4249 6.5551 4.1152 11.9029
SNU-719 CTRP2 4.4551 7.0295 3.9683 12.3768
MKN1 CTRP2 4.5672 5.1325 4.5656 11.376
Hs 746.T CTRP2 4.659 7.405 4.0255 11.6042
SNU-1 CTRP2 4.7237 6.4587 4.4719 9.704
MKN74 CTRP2 4.8374 5.9633 4.7484 8.3506
ECC12 CTRP2 5.1881 6.1761 5.0709 6.1204
LMSU CTRP2 5.3403 6.3399 5.179 5.2752
SH-10-TC CTRP2 5.3925 12.9656 2.0265 17.8369
KATO III CTRP2 5.403 6.3405 5.246 4.8438
MKN7 CTRP2 5.5846 6.1436 5.5123 3.3211
SNU-668 CTRP2 6.3314 9.397 4.6008 5.5359
MKN45 CTRP2 7.1796 8.278 5.6727 0.3272
NUGC-3 CTRP2 8.2108 10.2746 5.3477 0.5942
SNG-M CTRP2 4.8703 6.3367 4.6729 8.5281
SNU-1077 CTRP2 5.1064 6.7275 4.7779 7.4642
SNU-685 CTRP2 6.0724 7.0432 5.5681 1.9486
⏷ Show the Full List of 34 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 12 Cell Line(s) in Thyroid Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
SW579 CTRP2 2.6517 3.0853 2.6517 22.6025
TT2609-C02 CTRP2 3.8255 6.7212 3.4093 16.2772
TT CTRP2 4.1139 5.5072 4.0562 13.0581
8305C CTRP2 4.282 5.0793 4.2764 11.76
8505C CTRP2 4.3043 5.5683 4.251 11.7743
B-CPAP CTRP2 4.3936 5.0691 4.3908 11.0073
CAL-62 CTRP2 4.5861 5.0689 4.5856 9.717
CGTH-W-1 CTRP2 4.8438 5.7217 4.8061 8.1271
ML-1 [Human leukemia] CTRP2 4.9764 5.9626 4.9001 7.3799
FTC-238 CTRP2 5.3706 5.8529 5.3511 4.5556
FTC-133 CTRP2 5.5904 6.0186 5.5557 3.1451
BHT-101 CTRP2 6.0279 7.5417 5.282 3.2367
⏷ Show the Full List of 12 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 29 Cell Line(s) in Upper Aerodigestive Tract Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
Detroit 562 CTRP2 3.0736 4.5547 3.0573 19.8465
SCC-4 CTRP2 3.5099 6.1415 3.2513 17.7925
SCC-25 CTRP2 3.6391 5.8267 3.4756 16.5914
SNU-1214 CTRP2 3.8099 5.6019 3.7108 15.2267
BHY CTRP2 4.1205 5.2055 4.1008 12.8835
YD-10B CTRP2 4.179 5.5764 4.1147 12.647
CAL-33 CTRP2 4.2853 5.5063 4.2403 11.8723
HSC-3 CTRP2 4.368 7.82 3.5454 14.2609
YD-8 CTRP2 4.3779 5.361 4.3568 11.1736
SNU-1076 CTRP2 4.4353 4.9342 4.4349 10.7215
SNU-899 CTRP2 4.4467 7.225 3.8802 12.7406
BICR 16 CTRP2 4.7359 5.7457 4.6855 8.8898
PE/CA-PJ34 (clone C12) CTRP2 5.2082 6.424 5.0059 6.306
HSC-4 CTRP2 5.274 6.0196 5.2103 5.3546
PE/CA-PJ49 CTRP2 5.2883 6.0256 5.2243 5.2608
BICR 22 CTRP2 5.292 6.0148 5.2311 5.2248
HSC-2 CTRP2 5.3111 5.9495 5.2679 5.0347
SCC-9 CTRP2 5.3282 6.815 4.9716 6.1141
FaDu CTRP2 5.3796 5.8863 5.3552 4.5123
BICR 6 CTRP2 5.4052 5.8714 5.3853 4.3264
BICR 18 CTRP2 5.407 6.1417 5.32 4.5548
BICR 31 CTRP2 5.417 6.1217 5.3372 4.4622
CAL-27 CTRP2 5.4387 6.0747 5.3749 4.2592
PE/CA-PJ15 CTRP2 5.4913 6.0252 5.446 3.8428
PE/CA-PJ41 (clone D2) CTRP2 5.6053 6.0246 5.5705 3.0465
BICR 56 CTRP2 5.6598 6.1521 5.591 2.809
SNU-46 CTRP2 6.2592 16.338 1.0755 19.3887
SNU-1066 CTRP2 7.5056 9.4928 5.3318 1.0925
SNU-1041 CTRP2 8.7655 14.641 3.7466 5.4736
⏷ Show the Full List of 29 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 24 Cell Line(s) in Urinary Tract Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
U-BLC1 CTRP2 3.4115 4.6193 3.4024 17.5712
BFTC-905 CTRP2 3.6519 4.209 3.6519 15.9392
253J CTRP2 3.7229 4.7433 3.7167 15.487
VM-CUB-1 CTRP2 3.8217 13.5656 0.3019 27.1925
CAL-29 CTRP2 4.0207 5.2984 3.9859 13.5999
253J-BV CTRP2 4.0749 4.97 4.0684 13.1428
5637 CTRP2 4.1022 6.3807 3.8243 13.9265
TCCSUP CTRP2 4.2738 5.1296 4.2656 11.8236
BC-3C CTRP2 4.3944 7.3474 3.7746 13.2925
JMSU-1 CTRP2 4.3957 5.577 4.3478 11.1468
639V CTRP2 4.4858 4.8709 4.4858 10.3836
RT-112 CTRP2 4.5781 8.9918 3.2223 15.017
647V CTRP2 4.7505 5.4771 4.7375 8.664
KMBC-2 CTRP2 4.807 6.5451 4.5304 9.2451
UM-UC-3 CTRP2 5.0449 6.0886 4.9413 7.0226
SW1710 CTRP2 5.1213 7.1757 4.6007 8.1222
SCaBER CTRP2 5.2829 8.7808 3.9993 10.1869
HT-1197 CTRP2 5.4118 6.0037 5.3646 4.3785
J82 CTRP2 5.5148 6.2724 5.3914 3.9758
KU-19-19 CTRP2 5.5669 6.8606 5.1925 4.6234
UM-UC-1 CTRP2 5.9387 11.2192 3.3684 11.4215
T24 CTRP2 5.9586 9.6792 4.155 8.1072
HT-1376 CTRP2 6.8828 11.3253 4.0659 6.8262
RT-4 CTRP2 8.1397 11.0022 5.0171 1.5839
⏷ Show the Full List of 24 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Urogenital System Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
HeLa CTRP2 9.1961 19.2557 1.8449 11.8438

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Prochlorperazine
DDI Drug Name DDI Drug ID Severity Mechanism Disease REF
Droperidol DM0DXA8 Major Increased risk of prolong QT interval by the combination of Prochlorperazine and Droperidol. Nausea/vomiting [MD90] [12]
Dimenhydrinate DM264B3 Moderate Additive anticholinergic effects by the combination of Prochlorperazine and Dimenhydrinate. Nausea/vomiting [MD90] [13]
Promethazine DM6I5GR Moderate Additive anticholinergic effects by the combination of Prochlorperazine and Promethazine. Nausea/vomiting [MD90] [13]
Cyclizine DM9G7BS Moderate Additive anticholinergic effects by the combination of Prochlorperazine and Cyclizine. Nausea/vomiting [MD90] [13]
Metoclopramide DMFA5MY Major Additive antidopaminergic effects by the combination of Prochlorperazine and Metoclopramide. Nausea/vomiting [MD90] [14]
Dolasetron DMMG26Z Major Increased risk of prolong QT interval by the combination of Prochlorperazine and Dolasetron. Nausea/vomiting [MD90] [12]
Ondansetron DMOTQ1I Moderate Increased risk of prolong QT interval by the combination of Prochlorperazine and Ondansetron. Nausea/vomiting [MD90] [12]
⏷ Show the Full List of 7 DDI Information of This Drug
Coadministration of a Drug Treating the Disease Different from Prochlorperazine (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Ivosidenib DM8S6T7 Major Increased risk of prolong QT interval by the combination of Prochlorperazine and Ivosidenib. Acute myeloid leukaemia [2A60] [15]
Midostaurin DMI6E0R Moderate Increased risk of prolong QT interval by the combination of Prochlorperazine and Midostaurin. Acute myeloid leukaemia [2A60] [12]
Idarubicin DMM0XGL Moderate Increased risk of prolong QT interval by the combination of Prochlorperazine and Idarubicin. Acute myeloid leukaemia [2A60] [12]
Daunorubicin DMQUSBT Moderate Increased risk of prolong QT interval by the combination of Prochlorperazine and Daunorubicin. Acute myeloid leukaemia [2A60] [12]
Arn-509 DMT81LZ Moderate Increased risk of prolong QT interval by the combination of Prochlorperazine and Arn-509. Acute myeloid leukaemia [2A60] [16]
Gilteritinib DMTI0ZO Moderate Increased risk of prolong QT interval by the combination of Prochlorperazine and Gilteritinib. Acute myeloid leukaemia [2A60] [17]
Oliceridine DM6MDCF Moderate Increased risk of prolong QT interval by the combination of Prochlorperazine and Oliceridine. Acute pain [MG31] [12]
Mepyramine DMB4SFH Moderate Additive anticholinergic effects by the combination of Prochlorperazine and Mepyramine. Allergic/hypersensitivity disorder [4A80-4A8Z] [18]
Phenyltoloxamine DMKAEQW Moderate Additive anticholinergic effects by the combination of Prochlorperazine and Phenyltoloxamine. Allergic/hypersensitivity disorder [4A80-4A8Z] [18]
Tripelennamine DMZBU15 Moderate Additive anticholinergic effects by the combination of Prochlorperazine and Tripelennamine. Allergic/hypersensitivity disorder [4A80-4A8Z] [13]
Memantine DMD9WSC Moderate Additive anticholinergic effects by the combination of Prochlorperazine and Memantine. Alzheimer disease [8A20] [13]
Galantamine DMEO794 Moderate Antagonize the effect of Prochlorperazine when combined with Galantamine. Alzheimer disease [8A20] [19]
Rivastigmine DMG629M Moderate Antagonize the effect of Prochlorperazine when combined with Rivastigmine. Alzheimer disease [8A20] [19]
Donepezil DMIYG7Z Moderate Antagonize the effect of Prochlorperazine when combined with Donepezil. Alzheimer disease [8A20] [19]
Metronidazole DMTIVEN Minor Increased risk of prolong QT interval by the combination of Prochlorperazine and Metronidazole. Amoebiasis [1A36] [20]
Trimethaphan DMHF4IQ Moderate Additive hypotensive effects by the combination of Prochlorperazine and Trimethaphan. Aneurysm/dissection [BD50] [21]
Ivabradine DM0L594 Major Increased risk of ventricular arrhythmias by the combination of Prochlorperazine and Ivabradine. Angina pectoris [BA40] [16]
Bepridil DM0RKS4 Major Increased risk of prolong QT interval by the combination of Prochlorperazine and Bepridil. Angina pectoris [BA40] [12]
Dronedarone DMA8FS5 Major Increased risk of prolong QT interval by the combination of Prochlorperazine and Dronedarone. Angina pectoris [BA40] [12]
Amyl nitrite DMJKO05 Moderate Additive hypotensive effects by the combination of Prochlorperazine and Amyl nitrite. Angina pectoris [BA40] [22]
Nifedipine DMSVOZT Moderate Additive hypotensive effects by the combination of Prochlorperazine and Nifedipine. Angina pectoris [BA40] [22]
Bedaquiline DM3906J Major Increased risk of prolong QT interval by the combination of Prochlorperazine and Bedaquiline. Antimicrobial drug resistance [MG50-MG52] [23]
Hydroxyzine DMF8Y74 Moderate Additive anticholinergic effects by the combination of Prochlorperazine and Hydroxyzine. Anxiety disorder [6B00-6B0Z] [13]
Cilostazol DMZMSCT Moderate Increased risk of prolong QT interval by the combination of Prochlorperazine and Cilostazol. Arterial occlusive disease [BD40] [12]
Voriconazole DMAOL2S Moderate Increased risk of prolong QT interval by the combination of Prochlorperazine and Voriconazole. Aspergillosis [1F20] [12]
Levalbuterol DM5YBO1 Moderate Increased risk of prolong QT interval by the combination of Prochlorperazine and Levalbuterol. Asthma [CA23] [24]
Terbutaline DMD4381 Moderate Increased risk of ventricular arrhythmias by the combination of Prochlorperazine and Terbutaline. Asthma [CA23] [25]
Pirbuterol DMI5678 Moderate Increased risk of ventricular arrhythmias by the combination of Prochlorperazine and Pirbuterol. Asthma [CA23] [25]
Salbutamol DMN9CWF Moderate Increased risk of prolong QT interval by the combination of Prochlorperazine and Salbutamol. Asthma [CA23] [24]
Formoterol DMSOURV Moderate Increased risk of ventricular arrhythmias by the combination of Prochlorperazine and Formoterol. Asthma [CA23] [25]
Lisdexamfetamine DM6W8V5 Moderate Antagonize the effect of Prochlorperazine when combined with Lisdexamfetamine. Attention deficit hyperactivity disorder [6A05] [26]
Desipramine DMT2FDC Moderate Increased plasma concentrations of Prochlorperazine and Desipramine due to competitive inhibition of the same metabolic pathway. Attention deficit hyperactivity disorder [6A05] [27]
Ofloxacin DM0VQN3 Moderate Increased risk of prolong QT interval by the combination of Prochlorperazine and Ofloxacin. Bacterial infection [1A00-1C4Z] [28]
Ciprofloxacin XR DM2NLS9 Moderate Increased risk of prolong QT interval by the combination of Prochlorperazine and Ciprofloxacin XR. Bacterial infection [1A00-1C4Z] [12]
Clarithromycin DM4M1SG Moderate Increased risk of prolong QT interval by the combination of Prochlorperazine and Clarithromycin. Bacterial infection [1A00-1C4Z] [12]
Sulfamethoxazole DMB08GE Minor Increased risk of prolong QT interval by the combination of Prochlorperazine and Sulfamethoxazole. Bacterial infection [1A00-1C4Z] [12]
Sparfloxacin DMB4HCT Major Increased risk of prolong QT interval by the combination of Prochlorperazine and Sparfloxacin. Bacterial infection [1A00-1C4Z] [28]
Linezolid DMGFPU2 Moderate Additive CNS depression effects by the combination of Prochlorperazine and Linezolid. Bacterial infection [1A00-1C4Z] [29]
Gemifloxacin DMHT34O Moderate Increased risk of prolong QT interval by the combination of Prochlorperazine and Gemifloxacin. Bacterial infection [1A00-1C4Z] [28]
Levofloxacin DMS60RB Moderate Increased risk of prolong QT interval by the combination of Prochlorperazine and Levofloxacin. Bacterial infection [1A00-1C4Z] [28]
Lomefloxacin DMVRH9C Moderate Increased risk of prolong QT interval by the combination of Prochlorperazine and Lomefloxacin. Bacterial infection [1A00-1C4Z] [12]
Telithromycin DMZ4P3A Moderate Increased risk of prolong QT interval by the combination of Prochlorperazine and Telithromycin. Bacterial infection [1A00-1C4Z] [12]
Retigabine DMGNYIH Moderate Increased risk of prolong QT interval by the combination of Prochlorperazine and Retigabine. Behcet disease [4A62] [12]
Cariprazine DMJYDVK Moderate Additive anticholinergic effects by the combination of Prochlorperazine and Cariprazine. Bipolar disorder [6A60] [13]
Loperamide DMOJZQ9 Moderate Additive antimotility effects by the combination of Prochlorperazine and Loperamide. Bowel habit change [ME05] [30]
Eribulin DM1DX4Q Moderate Increased risk of prolong QT interval by the combination of Prochlorperazine and Eribulin. Breast cancer [2C60-2C6Y] [12]
Lapatinib DM3BH1Y Moderate Increased risk of prolong QT interval by the combination of Prochlorperazine and Lapatinib. Breast cancer [2C60-2C6Y] [12]
Tamoxifen DMLB0EZ Moderate Increased risk of prolong QT interval by the combination of Prochlorperazine and Tamoxifen. Breast cancer [2C60-2C6Y] [12]
Toremifene DMQYUWG Major Increased risk of prolong QT interval by the combination of Prochlorperazine and Toremifene. Breast cancer [2C60-2C6Y] [12]
Sotalol DML60TN Major Increased risk of prolong QT interval by the combination of Prochlorperazine and Sotalol. Cardiac arrhythmia [BC9Z] [12]
Acetylcholine DMDF79Z Moderate Antagonize the effect of Prochlorperazine when combined with Acetylcholine. Cataract [9B10] [31]
Umeclidinium DM4E8O9 Moderate Additive anticholinergic effects by the combination of Prochlorperazine and Umeclidinium. Chronic obstructive pulmonary disease [CA22] [32]
Olodaterol DM62B78 Moderate Increased risk of ventricular arrhythmias by the combination of Prochlorperazine and Olodaterol. Chronic obstructive pulmonary disease [CA22] [25]
Tiotropium DMFDC0Q Moderate Additive anticholinergic effects by the combination of Prochlorperazine and Tiotropium. Chronic obstructive pulmonary disease [CA22] [32]
Salmeterol DMIEU69 Moderate Increased risk of prolong QT interval by the combination of Prochlorperazine and Salmeterol. Chronic obstructive pulmonary disease [CA22] [25]
Revefenacin DMMP5SI Moderate Additive anticholinergic effects by the combination of Prochlorperazine and Revefenacin. Chronic obstructive pulmonary disease [CA22] [32]
Indacaterol DMQJHR7 Moderate Increased risk of ventricular arrhythmias by the combination of Prochlorperazine and Indacaterol. Chronic obstructive pulmonary disease [CA22] [25]
Arformoterol DMYM974 Moderate Increased risk of ventricular arrhythmias by the combination of Prochlorperazine and Arformoterol. Chronic obstructive pulmonary disease [CA22] [25]
Isoproterenol DMK7MEY Moderate Increased risk of ventricular arrhythmias by the combination of Prochlorperazine and Isoproterenol. Conduction disorder [BC63] [24]
Olopatadine DMKMWQG Moderate Additive CNS depression effects by the combination of Prochlorperazine and Olopatadine. Conjunctiva disorder [9A60] [33]
Propofol DMB4OLE Moderate Increased risk of prolong QT interval by the combination of Prochlorperazine and Propofol. Corneal disease [9A76-9A78] [34]
Sevoflurane DMC9O43 Moderate Increased risk of prolong QT interval by the combination of Prochlorperazine and Sevoflurane. Corneal disease [9A76-9A78] [12]
Probucol DMVZQ2M Moderate Increased risk of prolong QT interval by the combination of Prochlorperazine and Probucol. Coronary atherosclerosis [BA80] [12]
Clofazimine DMEBOFW Moderate Increased risk of prolong QT interval by the combination of Prochlorperazine and Clofazimine. Crohn disease [DD70] [35]
Mifepristone DMGZQEF Major Increased risk of prolong QT interval by the combination of Prochlorperazine and Mifepristone. Cushing syndrome [5A70] [12]
Pasireotide DMHM7JS Major Increased risk of prolong QT interval by the combination of Prochlorperazine and Pasireotide. Cushing syndrome [5A70] [12]
Cyclandelate DMO0R76 Moderate Additive hypotensive effects by the combination of Prochlorperazine and Cyclandelate. Dementia [6D80-6D8Z] [22]
Sertraline DM0FB1J Moderate Increased risk of prolong QT interval by the combination of Prochlorperazine and Sertraline. Depression [6A70-6A7Z] [12]
Cyclobenzaprine DM1YBRM Moderate Additive anticholinergic effects by the combination of Prochlorperazine and Cyclobenzaprine. Depression [6A70-6A7Z] [13]
Imipramine DM2NUH3 Moderate Increased plasma concentrations of Prochlorperazine and Imipramine due to competitive inhibition of the same metabolic pathway. Depression [6A70-6A7Z] [27]
Fluoxetine DM3PD2C Moderate Additive antidopaminergic effects by the combination of Prochlorperazine and Fluoxetine. Depression [6A70-6A7Z] [36]
Nortriptyline DM4KDYJ Moderate Increased plasma concentrations of Prochlorperazine and Nortriptyline due to competitive inhibition of the same metabolic pathway. Depression [6A70-6A7Z] [27]
Paroxetine DM5PVQE Moderate Decreased metabolism of Prochlorperazine caused by Paroxetine mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [37]
Selegiline DM6034S Moderate Additive CNS depression effects by the combination of Prochlorperazine and Selegiline. Depression [6A70-6A7Z] [29]
Duloxetine DM9BI7M Moderate Decreased metabolism of Prochlorperazine caused by Duloxetine mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [38]
Isocarboxazid DMAF1NB Moderate Additive hypotensive effects by the combination of Prochlorperazine and Isocarboxazid. Depression [6A70-6A7Z] [29]
Tranylcypromine DMGB5RE Moderate Additive CNS depression effects by the combination of Prochlorperazine and Tranylcypromine. Depression [6A70-6A7Z] [29]
OPC-34712 DMHG57U Moderate Additive anticholinergic effects by the combination of Prochlorperazine and OPC-34712. Depression [6A70-6A7Z] [13]
Phenelzine DMHIDUE Moderate Additive CNS depression effects by the combination of Prochlorperazine and Phenelzine. Depression [6A70-6A7Z] [29]
Clomipramine DMINRKW Moderate Increased plasma concentrations of Prochlorperazine and Clomipramine due to competitive inhibition of the same metabolic pathway. Depression [6A70-6A7Z] [27]
Trazodone DMK1GBJ Moderate Increased risk of prolong QT interval by the combination of Prochlorperazine and Trazodone. Depression [6A70-6A7Z] [39]
Amoxapine DMKITQE Moderate Increased plasma concentrations of Prochlorperazine and Amoxapine due to competitive inhibition of the same metabolic pathway. Depression [6A70-6A7Z] [27]
Doxepin DMPI98T Moderate Increased plasma concentrations of Prochlorperazine and Doxepin due to competitive inhibition of the same metabolic pathway. Depression [6A70-6A7Z] [40]
Maprotiline DMPWB7T Moderate Additive anticholinergic effects by the combination of Prochlorperazine and Maprotiline. Depression [6A70-6A7Z] [13]
Esketamine DMVU687 Moderate Additive CNS depression effects by the combination of Prochlorperazine and Esketamine. Depression [6A70-6A7Z] [20]
Nitroglycerin DMQ2491 Moderate Additive hypotensive effects by the combination of Prochlorperazine and Nitroglycerin. Diabetic foot ulcer [BD54] [22]
Mepenzolate DM8YU2F Moderate Additive anticholinergic effects by the combination of Prochlorperazine and Mepenzolate. Digestive system disease [DE2Z] [13]
Oxybutynine DMJPBAX Moderate Additive anticholinergic effects by the combination of Prochlorperazine and Oxybutynine. Discovery agent [N.A.] [13]
Tetrabenazine DMYWQ0O Major Additive antidopaminergic effects by the combination of Prochlorperazine and Tetrabenazine. Dissociative neurological symptom disorder [6B60] [41]
Meclizine DMS7T13 Moderate Additive anticholinergic effects by the combination of Prochlorperazine and Meclizine. Dizziness and giddiness [MB48] [13]
Deutetrabenazine DMUPFLI Major Additive antidopaminergic effects by the combination of Prochlorperazine and Deutetrabenazine. Dystonic disorder [8A02] [42]
Ingrezza DMVPLNC Moderate Increased risk of prolong QT interval by the combination of Prochlorperazine and Ingrezza. Dystonic disorder [8A02] [43]
Zonisamide DM0DTF7 Major Increased risk of hyperpyrexia by the combination of Prochlorperazine and Zonisamide. Epilepsy/seizure [8A61-8A6Z] [44]
Stiripentol DMMSDOY Moderate Decreased metabolism of Prochlorperazine caused by Stiripentol mediated inhibition of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [45]
Guanabenz DM5QWEL Moderate Additive hypotensive effects by the combination of Prochlorperazine and Guanabenz. Essential hypertension [BA00] [22]
Ethacrynic acid DM60QMR Moderate Additive hypotensive effects by the combination of Prochlorperazine and Ethacrynic acid. Essential hypertension [BA00] [21]
Bendroflumethiazide DM7EVLC Moderate Increased risk of ventricular arrhythmias by the combination of Prochlorperazine and Bendroflumethiazide. Essential hypertension [BA00] [20]
Phenoxybenzamine DM8KSQH Moderate Additive hypotensive effects by the combination of Prochlorperazine and Phenoxybenzamine. Essential hypertension [BA00] [22]
Nicardipine DMCDYW7 Moderate Additive hypotensive effects by the combination of Prochlorperazine and Nicardipine. Essential hypertension [BA00] [22]
Mecamylamine DMGQFYB Moderate Additive hypotensive effects by the combination of Prochlorperazine and Mecamylamine. Essential hypertension [BA00] [22]
Benzthiazide DMQWZ0H Moderate Increased risk of ventricular arrhythmias by the combination of Prochlorperazine and Benzthiazide. Essential hypertension [BA00] [20]
Nadolol DMW6GVL Moderate Additive hypotensive effects by the combination of Prochlorperazine and Nadolol. Essential hypertension [BA00] [22]
Solifenacin DMG592Q Moderate Increased risk of prolong QT interval by the combination of Prochlorperazine and Solifenacin. Functional bladder disorder [GC50] [12]
Mirabegron DMS1GYT Moderate Decreased metabolism of Prochlorperazine caused by Mirabegron mediated inhibition of CYP450 enzyme. Functional bladder disorder [GC50] [46]
Tolterodine DMSHPW8 Moderate Additive anticholinergic effects by the combination of Prochlorperazine and Tolterodine. Functional bladder disorder [GC50] [13]
Darifenacin DMWXLYZ Moderate Decreased metabolism of Prochlorperazine caused by Darifenacin mediated inhibition of CYP450 enzyme. Functional bladder disorder [GC50] [47]
Pentamidine DMHZJCG Moderate Increased risk of prolong QT interval by the combination of Prochlorperazine and Pentamidine. Fungal infection [1F29-1F2F] [12]
Terbinafine DMI6HUW Moderate Decreased metabolism of Prochlorperazine caused by Terbinafine mediated inhibition of CYP450 enzyme. Fungal infection [1F29-1F2F] [48]
Ketoconazole DMPZI3Q Moderate Increased risk of prolong QT interval by the combination of Prochlorperazine and Ketoconazole. Fungal infection [1F29-1F2F] [12]
Phentolamine DMXYJOB Moderate Additive hypotensive effects by the combination of Prochlorperazine and Phentolamine. Gangrene [MC85] [22]
Cisapride DMY7PED Major Increased risk of prolong QT interval by the combination of Prochlorperazine and Cisapride. Gastro-oesophageal reflux disease [DA22] [12]
Sunitinib DMCBJSR Moderate Increased risk of prolong QT interval by the combination of Prochlorperazine and Sunitinib. Gastrointestinal stromal tumour [2B5B] [12]
Isoflurophate DMBSK7X Moderate Antagonize the effect of Prochlorperazine when combined with Isoflurophate. Glaucoma [9C61] [31]
Carteolol DMFMDOB Moderate Additive hypotensive effects by the combination of Prochlorperazine and Carteolol. Glaucoma [9C61] [22]
Brimonidine DMQLT4N Moderate Additive CNS depression effects by the combination of Prochlorperazine and Brimonidine. Glaucoma [9C61] [49]
Pilocarpine DMV9ADG Moderate Antagonize the effect of Prochlorperazine when combined with Pilocarpine. Glaucoma [9C61] [31]
Prazosin DMCD9YG Moderate Additive hypotensive effects by the combination of Prochlorperazine and Prazosin. Heart failure [BD10-BD1Z] [22]
Eplerenone DMF0NQR Moderate Additive hypotensive effects by the combination of Prochlorperazine and Eplerenone. Heart failure [BD10-BD1Z] [22]
Carvedilol DMHTEAO Moderate Additive hypotensive effects by the combination of Prochlorperazine and Carvedilol. Heart failure [BD10-BD1Z] [22]
Chlorothiazide DMLHESP Moderate Increased risk of ventricular arrhythmias by the combination of Prochlorperazine and Chlorothiazide. Heart failure [BD10-BD1Z] [20]
Furosemide DMMQ8ZG Moderate Increased risk of ventricular arrhythmias by the combination of Prochlorperazine and Furosemide. Heart failure [BD10-BD1Z] [20]
Amiloride DMRTSGP Moderate Additive hypotensive effects by the combination of Prochlorperazine and Amiloride. Heart failure [BD10-BD1Z] [22]
Bumetanide DMRV7H0 Moderate Increased risk of ventricular arrhythmias by the combination of Prochlorperazine and Bumetanide. Heart failure [BD10-BD1Z] [20]
Hydroflumethiazide DMVPUQI Moderate Increased risk of ventricular arrhythmias by the combination of Prochlorperazine and Hydroflumethiazide. Heart failure [BD10-BD1Z] [20]
Procarbazine DMIK367 Moderate Additive hypotensive effects by the combination of Prochlorperazine and Procarbazine. Hodgkin lymphoma [2B30] [29]
Fostemsavir DM50ILT Moderate Increased risk of prolong QT interval by the combination of Prochlorperazine and Fostemsavir. Human immunodeficiency virus disease [1C60-1C62] [50]
Cobicistat DM6L4H2 Moderate Decreased metabolism of Prochlorperazine caused by Cobicistat mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [51]
Efavirenz DMC0GSJ Major Increased risk of prolong QT interval by the combination of Prochlorperazine and Efavirenz. Human immunodeficiency virus disease [1C60-1C62] [52]
Saquinavir DMG814N Major Increased risk of prolong QT interval by the combination of Prochlorperazine and Saquinavir. Human immunodeficiency virus disease [1C60-1C62] [53]
Rilpivirine DMJ0QOW Moderate Increased risk of prolong QT interval by the combination of Prochlorperazine and Rilpivirine. Human immunodeficiency virus disease [1C60-1C62] [12]
Isosorbide mononitrate DMYLMU0 Moderate Additive hypotensive effects by the combination of Prochlorperazine and Isosorbide mononitrate. Hydrocephalus [8D64] [22]
Cinacalcet DMCX0K3 Moderate Decreased metabolism of Prochlorperazine caused by Cinacalcet mediated inhibition of CYP450 enzyme. Hyper-parathyroidism [5A51] [20]
Eprosartan DM07K2I Moderate Additive hypotensive effects by the combination of Prochlorperazine and Eprosartan. Hypertension [BA00-BA04] [22]
Acebutolol DM0TI4U Moderate Additive hypotensive effects by the combination of Prochlorperazine and Acebutolol. Hypertension [BA00-BA04] [22]
Moexipril DM26E4B Moderate Additive hypotensive effects by the combination of Prochlorperazine and Moexipril. Hypertension [BA00-BA04] [22]
Bisoprolol DM3UZ95 Moderate Additive hypotensive effects by the combination of Prochlorperazine and Bisoprolol. Hypertension [BA00-BA04] [22]
Captopril DM458UM Moderate Additive hypotensive effects by the combination of Prochlorperazine and Captopril. Hypertension [BA00-BA04] [22]
Penbutolol DM4ES8F Moderate Additive hypotensive effects by the combination of Prochlorperazine and Penbutolol. Hypertension [BA00-BA04] [22]
Trandolapril DM4L6EU Moderate Additive hypotensive effects by the combination of Prochlorperazine and Trandolapril. Hypertension [BA00-BA04] [22]
Methyldopa DM5I621 Moderate Additive hypotensive effects by the combination of Prochlorperazine and Methyldopa. Hypertension [BA00-BA04] [22]
Clonidine DM6RZ9Q Moderate Additive hypotensive effects by the combination of Prochlorperazine and Clonidine. Hypertension [BA00-BA04] [22]
Losartan DM72JXH Moderate Additive hypotensive effects by the combination of Prochlorperazine and Losartan. Hypertension [BA00-BA04] [22]
Nebivolol DM7F1PA Moderate Additive hypotensive effects by the combination of Prochlorperazine and Nebivolol. Hypertension [BA00-BA04] [22]
Levamlodipine DM92S6N Moderate Additive hypotensive effects by the combination of Prochlorperazine and Levamlodipine. Hypertension [BA00-BA04] [22]
Fosinopril DM9NJ52 Moderate Additive hypotensive effects by the combination of Prochlorperazine and Fosinopril. Hypertension [BA00-BA04] [22]
Doxazosin DM9PLRH Moderate Additive hypotensive effects by the combination of Prochlorperazine and Doxazosin. Hypertension [BA00-BA04] [22]
Verapamil DMA7PEW Moderate Additive hypotensive effects by the combination of Prochlorperazine and Verapamil. Hypertension [BA00-BA04] [22]
TAK-491 DMCF6SX Moderate Additive hypotensive effects by the combination of Prochlorperazine and TAK-491. Hypertension [BA00-BA04] [22]
Pindolol DMD2NV7 Moderate Additive hypotensive effects by the combination of Prochlorperazine and Pindolol. Hypertension [BA00-BA04] [22]
Fenoldopam DMFAOKP Moderate Additive hypotensive effects by the combination of Prochlorperazine and Fenoldopam. Hypertension [BA00-BA04] [22]
Indapamide DMGN1PW Moderate Increased risk of ventricular arrhythmias by the combination of Prochlorperazine and Indapamide. Hypertension [BA00-BA04] [20]
Benazepril DMH1M9B Moderate Additive hypotensive effects by the combination of Prochlorperazine and Benazepril. Hypertension [BA00-BA04] [22]
Trichlormethiazide DMHAQCO Moderate Additive hypotensive effects by the combination of Prochlorperazine and Trichlormethiazide. Hypertension [BA00-BA04] [22]
Labetalol DMK8U72 Moderate Additive hypotensive effects by the combination of Prochlorperazine and Labetalol. Hypertension [BA00-BA04] [22]
Diazoxide DML1538 Moderate Additive hypotensive effects by the combination of Prochlorperazine and Diazoxide. Hypertension [BA00-BA04] [22]
Enalapril DMNFUZR Moderate Additive hypotensive effects by the combination of Prochlorperazine and Enalapril. Hypertension [BA00-BA04] [22]
Perindopril DMOPZDT Moderate Additive hypotensive effects by the combination of Prochlorperazine and Perindopril. Hypertension [BA00-BA04] [22]
Felodipine DMOSW35 Moderate Additive hypotensive effects by the combination of Prochlorperazine and Felodipine. Hypertension [BA00-BA04] [22]
Quinapril DMR8H31 Moderate Additive hypotensive effects by the combination of Prochlorperazine and Quinapril. Hypertension [BA00-BA04] [22]
Deserpidine DMRH7CV Moderate Additive hypotensive effects by the combination of Prochlorperazine and Deserpidine. Hypertension [BA00-BA04] [22]
Telmisartan DMS3GX2 Moderate Additive hypotensive effects by the combination of Prochlorperazine and Telmisartan. Hypertension [BA00-BA04] [22]
Irbesartan DMTP1DC Moderate Additive hypotensive effects by the combination of Prochlorperazine and Irbesartan. Hypertension [BA00-BA04] [22]
Hydralazine DMU8JGH Moderate Additive hypotensive effects by the combination of Prochlorperazine and Hydralazine. Hypertension [BA00-BA04] [22]
Lisinopril DMUOK4C Moderate Additive hypotensive effects by the combination of Prochlorperazine and Lisinopril. Hypertension [BA00-BA04] [22]
Hydrochlorothiazide DMUSZHD Moderate Increased risk of ventricular arrhythmias by the combination of Prochlorperazine and Hydrochlorothiazide. Hypertension [BA00-BA04] [20]
Clevidipine butyrate DMW4M97 Moderate Additive hypotensive effects by the combination of Prochlorperazine and Clevidipine butyrate. Hypertension [BA00-BA04] [22]
Belladonna DM2RBWK Moderate Additive anticholinergic effects by the combination of Prochlorperazine and Belladonna. Infectious gastroenteritis/colitis [1A40] [13]
Amantadine DMS3YE9 Moderate Additive anticholinergic effects by the combination of Prochlorperazine and Amantadine. Influenza [1E30-1E32] [54]
Propiomazine DMKY8V1 Moderate Additive anticholinergic effects by the combination of Prochlorperazine and Propiomazine. Insomnia [7A00-7A0Z] [13]
ITI-007 DMUQ1DO Moderate Additive anticholinergic effects by the combination of Prochlorperazine and ITI-007. Insomnia [7A00-7A0Z] [13]
Polyethylene glycol DM4I1JP Moderate Increased risk of ventricular arrhythmias by the combination of Prochlorperazine and Polyethylene glycol. Irritable bowel syndrome [DD91] [12]
Phenolphthalein DM5SICT Moderate Increased risk of ventricular arrhythmias by the combination of Prochlorperazine and Phenolphthalein. Irritable bowel syndrome [DD91] [12]
Clidinium DMUMQZ0 Moderate Additive anticholinergic effects by the combination of Prochlorperazine and Clidinium. Irritable bowel syndrome [DD91] [13]
Physostigmine DM2N0TO Moderate Antagonize the effect of Prochlorperazine when combined with Physostigmine. Lips/oral mucosa miscellaneous disorder [DA02] [19]
Glycerol phenylbutyrate DMDGRQO Moderate Decreased metabolism of Prochlorperazine caused by Glycerol phenylbutyrate mediated inhibition of CYP450 enzyme. Liver disease [DB90-DB9Z] [16]
Crizotinib DM4F29C Major Increased risk of prolong QT interval by the combination of Prochlorperazine and Crizotinib. Lung cancer [2C25] [55]
Porfimer Sodium DM7ZWNY Moderate Increased risk of photosensitivity reactions by the combination of Prochlorperazine and Porfimer Sodium. Lung cancer [2C25] [56]
Ceritinib DMB920Z Major Increased risk of prolong QT interval by the combination of Prochlorperazine and Ceritinib. Lung cancer [2C25] [12]
Osimertinib DMRJLAT Major Increased risk of prolong QT interval by the combination of Prochlorperazine and Osimertinib. Lung cancer [2C25] [57]
Selpercatinib DMZR15V Major Increased risk of prolong QT interval by the combination of Prochlorperazine and Selpercatinib. Lung cancer [2C25] [16]
Lumefantrine DM29GAD Major Increased risk of prolong QT interval by the combination of Prochlorperazine and Lumefantrine. Malaria [1F40-1F45] [20]
Halofantrine DMOMK1V Major Increased risk of prolong QT interval by the combination of Prochlorperazine and Halofantrine. Malaria [1F40-1F45] [58]
Chloroquine DMSI5CB Major Increased risk of prolong QT interval by the combination of Prochlorperazine and Chloroquine. Malaria [1F40-1F45] [59]
Hydroxychloroquine DMSIVND Major Increased risk of prolong QT interval by the combination of Prochlorperazine and Hydroxychloroquine. Malaria [1F40-1F45] [59]
Quinine DMSWYF5 Moderate Increased risk of prolong QT interval by the combination of Prochlorperazine and Quinine. Malaria [1F40-1F45] [12]
Primaquine DMWQ16I Moderate Increased risk of prolong QT interval by the combination of Prochlorperazine and Primaquine. Malaria [1F40-1F45] [12]
Inotuzumab ozogamicin DMAC130 Moderate Increased risk of prolong QT interval by the combination of Prochlorperazine and Inotuzumab ozogamicin. Malignant haematopoietic neoplasm [2B33] [16]
Arsenic trioxide DM61TA4 Major Increased risk of prolong QT interval by the combination of Prochlorperazine and Arsenic trioxide. Mature B-cell lymphoma [2A85] [60]
Vemurafenib DM62UG5 Major Increased risk of prolong QT interval by the combination of Prochlorperazine and Vemurafenib. Melanoma [2C30] [12]
LGX818 DMNQXV8 Moderate Increased risk of prolong QT interval by the combination of Prochlorperazine and LGX818. Melanoma [2C30] [61]
Allopregnanolone DMNLHAC Moderate Additive CNS depression effects by the combination of Prochlorperazine and Allopregnanolone. Mental/behavioural/neurodevelopmental disorder [6E20-6E8Z] [62]
Propranolol DM79NTF Moderate Additive hypotensive effects by the combination of Prochlorperazine and Propranolol. Migraine [8A80] [22]
Lasmiditan DMXLVDT Moderate Additive CNS depression effects by the combination of Prochlorperazine and Lasmiditan. Migraine [8A80] [63]
Flibanserin DM70DTN Moderate Additive CNS depression effects by the combination of Prochlorperazine and Flibanserin. Mood disorder [6A60-6E23] [64]
Panobinostat DM58WKG Major Increased risk of prolong QT interval by the combination of Prochlorperazine and Panobinostat. Multiple myeloma [2A83] [65]
Thalidomide DM70BU5 Moderate Additive CNS depression effects by the combination of Prochlorperazine and Thalidomide. Multiple myeloma [2A83] [66]
Fingolimod DM5JVAN Major Increased risk of ventricular arrhythmias by the combination of Prochlorperazine and Fingolimod. Multiple sclerosis [8A40] [12]
Ozanimod DMT6AM2 Major Increased risk of ventricular arrhythmias by the combination of Prochlorperazine and Ozanimod. Multiple sclerosis [8A40] [67]
Methoxsalen DME8FZ9 Moderate Increased risk of photosensitivity reactions by the combination of Prochlorperazine and Methoxsalen. Mycosis fungoides [2B01] [20]
Romidepsin DMT5GNL Moderate Increased risk of prolong QT interval by the combination of Prochlorperazine and Romidepsin. Mycosis fungoides [2B01] [12]
Nilotinib DM7HXWT Major Increased risk of prolong QT interval by the combination of Prochlorperazine and Nilotinib. Myeloproliferative neoplasm [2A20] [12]
Imatinib DM7RJXL Moderate Decreased metabolism of Prochlorperazine caused by Imatinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [68]
Dextroamphetamine DMMIHVP Moderate Antagonize the effect of Prochlorperazine when combined with Dextroamphetamine. Narcolepsy [7A20] [26]
Bupropion DM5PCS7 Major Decreased metabolism of Prochlorperazine caused by Bupropion mediated inhibition of CYP450 enzyme. Nicotine use disorder [6C4A] [12]
Entrectinib DMMPTLH Moderate Increased risk of prolong QT interval by the combination of Prochlorperazine and Entrectinib. Non-small cell lung cancer [2C25] [20]
Phendimetrazine DM6TS1N Moderate Antagonize the effect of Prochlorperazine when combined with Phendimetrazine. Obesity [5B80-5B81] [26]
Amfepramone DM9YSNQ Moderate Antagonize the effect of Prochlorperazine when combined with Amfepramone. Obesity [5B80-5B81] [26]
Lorcaserin DMG6OYJ Moderate Decreased metabolism of Prochlorperazine caused by Lorcaserin mediated inhibition of CYP450 enzyme. Obesity [5B80-5B81] [69]
Benzphetamine DMIJATC Moderate Antagonize the effect of Prochlorperazine when combined with Benzphetamine. Obesity [5B80-5B81] [26]
Mazindol DMZ36RN Moderate Antagonize the effect of Prochlorperazine when combined with Mazindol. Obesity [5B80-5B81] [26]
Metolazone DMB39LO Moderate Increased risk of ventricular arrhythmias by the combination of Prochlorperazine and Metolazone. Oedema [MG29] [20]
Polythiazide DMCH80F Moderate Increased risk of ventricular arrhythmias by the combination of Prochlorperazine and Polythiazide. Oedema [MG29] [20]
Levomethadyl Acetate DM06HG5 Major Increased risk of prolong QT interval by the combination of Prochlorperazine and Levomethadyl Acetate. Opioid use disorder [6C43] [16]
Lofexidine DM1WXA6 Moderate Increased risk of prolong QT interval by the combination of Prochlorperazine and Lofexidine. Opioid use disorder [6C43] [12]
Apraclonidine DMO4PVE Moderate Additive CNS depression effects by the combination of Prochlorperazine and Apraclonidine. Optic nerve disorder [9C40] [49]
Rucaparib DM9PVX8 Moderate Increased risk of prolong QT interval by the combination of Prochlorperazine and Rucaparib. Ovarian cancer [2C73] [12]
Dextropropoxyphene DM23HCX Major Additive CNS depression effects by the combination of Prochlorperazine and Dextropropoxyphene. Pain [MG30-MG3Z] [70]
Flavoxate DMKV4NL Moderate Additive anticholinergic effects by the combination of Prochlorperazine and Flavoxate. Pain [MG30-MG3Z] [13]
Methamphetamine DMPM4SK Moderate Antagonize the effect of Prochlorperazine when combined with Methamphetamine. Pain [MG30-MG3Z] [71]
Buprenorphine DMPRI8G Major Additive CNS depression effects by the combination of Prochlorperazine and Buprenorphine. Pain [MG30-MG3Z] [72]
Meperidine DMX4GND Moderate Additive CNS depression effects by the combination of Prochlorperazine and Meperidine. Pain [MG30-MG3Z] [73]
Triclabendazole DMPWGBR Moderate Increased risk of prolong QT interval by the combination of Prochlorperazine and Triclabendazole. Parasitic worm infestation [1F90] [12]
Pergolide DM14MAE Moderate Antagonize the effect of Prochlorperazine when combined with Pergolide. Parkinsonism [8A00] [74]
Opicapone DM1BKA6 Moderate Antagonize the effect of Prochlorperazine when combined with Opicapone. Parkinsonism [8A00] [74]
Rasagiline DM3WKQ4 Moderate Additive hypotensive effects by the combination of Prochlorperazine and Rasagiline. Parkinsonism [8A00] [29]
Biperiden DME78OA Moderate Antagonize the effect of Prochlorperazine when combined with Biperiden. Parkinsonism [8A00] [75]
Entacapone DMLBVKQ Moderate Antagonize the effect of Prochlorperazine when combined with Entacapone. Parkinsonism [8A00] [74]
Levodopa DMN3E57 Moderate Antagonize the effect of Prochlorperazine when combined with Levodopa. Parkinsonism [8A00] [74]
Pimavanserin DMR7IVC Moderate Increased risk of prolong QT interval by the combination of Prochlorperazine and Pimavanserin. Parkinsonism [8A00] [76]
Bromocriptine DMVE3TK Moderate Antagonize the effect of Prochlorperazine when combined with Bromocriptine. Parkinsonism [8A00] [74]
Orphenadrine DMW542E Moderate Additive anticholinergic effects by the combination of Prochlorperazine and Orphenadrine. Parkinsonism [8A00] [13]
Methylscopolamine DM5VWOB Moderate Additive anticholinergic effects by the combination of Prochlorperazine and Methylscopolamine. Peptic ulcer [DA61] [13]
Famotidine DMRL3AB Moderate Increased risk of prolong QT interval by the combination of Prochlorperazine and Famotidine. Peptic ulcer [DA61] [20]
Macimorelin DMQYJIR Major Increased risk of prolong QT interval by the combination of Prochlorperazine and Macimorelin. Pituitary gland disorder [5A60-5A61] [77]
Ritodrine DM4V6RL Moderate Increased risk of prolong QT interval by the combination of Prochlorperazine and Ritodrine. Preterm labour/delivery [JB00] [25]
Degarelix DM3O8QY Moderate Increased risk of prolong QT interval by the combination of Prochlorperazine and Degarelix. Prostate cancer [2C82] [16]
ABIRATERONE DM8V75C Moderate Decreased metabolism of Prochlorperazine caused by ABIRATERONE mediated inhibition of CYP450 enzyme. Prostate cancer [2C82] [78]
Nilutamide DMFN07X Moderate Increased risk of prolong QT interval by the combination of Prochlorperazine and Nilutamide. Prostate cancer [2C82] [16]
Enzalutamide DMGL19D Moderate Increased risk of prolong QT interval by the combination of Prochlorperazine and Enzalutamide. Prostate cancer [2C82] [16]
Flutamide DMK0O7U Moderate Increased risk of prolong QT interval by the combination of Prochlorperazine and Flutamide. Prostate cancer [2C82] [16]
Relugolix DMK7IWL Moderate Increased risk of prolong QT interval by the combination of Prochlorperazine and Relugolix. Prostate cancer [2C82] [16]
Bicalutamide DMZMSPF Moderate Increased risk of prolong QT interval by the combination of Prochlorperazine and Bicalutamide. Prostate cancer [2C82] [16]
Terazosin DM3JCVS Moderate Additive hypotensive effects by the combination of Prochlorperazine and Terazosin. Prostate hyperplasia [GA90] [22]
Tamsulosin DM5QF9V Moderate Additive hypotensive effects by the combination of Prochlorperazine and Tamsulosin. Prostate hyperplasia [GA90] [22]
Silodosin DMJSBT6 Moderate Additive hypotensive effects by the combination of Prochlorperazine and Silodosin. Prostate hyperplasia [GA90] [22]
Verteporfin DMIY6DB Moderate Increased risk of photosensitivity reactions by the combination of Prochlorperazine and Verteporfin. Psoriasis [EA90] [16]
Levomepromazine DMIKFEL Moderate Additive anticholinergic effects by the combination of Prochlorperazine and Levomepromazine. Psychotic disorder [6A20-6A25] [13]
Fluphenazine DMIT8LX Moderate Additive anticholinergic effects by the combination of Prochlorperazine and Fluphenazine. Psychotic disorder [6A20-6A25] [13]
Triflupromazine DMKFQJP Moderate Additive anticholinergic effects by the combination of Prochlorperazine and Triflupromazine. Psychotic disorder [6A20-6A25] [13]
Tolazoline DMI40NL Moderate Additive hypotensive effects by the combination of Prochlorperazine and Tolazoline. Pulmonary hypertension [BB01] [22]
Gatifloxacin DMSL679 Major Increased risk of prolong QT interval by the combination of Prochlorperazine and Gatifloxacin. Respiratory infection [CA07-CA4Z] [79]
Neupro DMHEAB1 Moderate Antagonize the effect of Prochlorperazine when combined with Neupro. Restless legs syndrome [7A80] [74]
Celecoxib DM6LOQU Moderate Decreased metabolism of Prochlorperazine caused by Celecoxib mediated inhibition of CYP450 enzyme. Rheumatoid arthritis [FA20] [80]
Cyproheptadine DM92AH3 Moderate Additive anticholinergic effects by the combination of Prochlorperazine and Cyproheptadine. Rheumatoid arthritis [FA20] [13]
Quetiapine DM1N62C Moderate Increased risk of prolong QT interval by the combination of Prochlorperazine and Quetiapine. Schizophrenia [6A20] [12]
Mesoridazine DM2ZGAN Major Increased risk of prolong QT interval by the combination of Prochlorperazine and Mesoridazine. Schizophrenia [6A20] [12]
Thioridazine DM35M8J Major Increased risk of prolong QT interval by the combination of Prochlorperazine and Thioridazine. Schizophrenia [6A20] [81]
Aripiprazole DM3NUMH Moderate Additive anticholinergic effects by the combination of Prochlorperazine and Aripiprazole. Schizophrenia [6A20] [13]
Iloperidone DM6AUFY Major Increased risk of prolong QT interval by the combination of Prochlorperazine and Iloperidone. Schizophrenia [6A20] [12]
Paliperidone DM7NPJS Moderate Increased risk of prolong QT interval by the combination of Prochlorperazine and Paliperidone. Schizophrenia [6A20] [12]
Haloperidol DM96SE0 Major Increased risk of prolong QT interval by the combination of Prochlorperazine and Haloperidol. Schizophrenia [6A20] [12]
Perphenazine DMA4MRX Moderate Additive anticholinergic effects by the combination of Prochlorperazine and Perphenazine. Schizophrenia [6A20] [13]
Molindone DMAH70G Moderate Additive anticholinergic effects by the combination of Prochlorperazine and Molindone. Schizophrenia [6A20] [13]
Chlorpromazine DMBGZI3 Moderate Additive anticholinergic effects by the combination of Prochlorperazine and Chlorpromazine. Schizophrenia [6A20] [13]
Thiothixene DMDINC4 Moderate Additive anticholinergic effects by the combination of Prochlorperazine and Thiothixene. Schizophrenia [6A20] [13]
Trifluoperazine DMKBYWI Moderate Additive anticholinergic effects by the combination of Prochlorperazine and Trifluoperazine. Schizophrenia [6A20] [13]
Risperidone DMN6DXL Moderate Additive anticholinergic effects by the combination of Prochlorperazine and Risperidone. Schizophrenia [6A20] [13]
Amisulpride DMSJVAM Major Increased risk of prolong QT interval by the combination of Prochlorperazine and Amisulpride. Schizophrenia [6A20] [82]
Asenapine DMSQZE2 Moderate Increased risk of prolong QT interval by the combination of Prochlorperazine and Asenapine. Schizophrenia [6A20] [12]
Pimozide DMW83TP Major Increased risk of prolong QT interval by the combination of Prochlorperazine and Pimozide. Schizophrenia [6A20] [16]
Vardenafil DMTBGW8 Moderate Increased risk of prolong QT interval by the combination of Prochlorperazine and Vardenafil. Sexual dysfunction [HA00-HA01] [12]
LEE011 DMMX75K Major Increased risk of prolong QT interval by the combination of Prochlorperazine and LEE011. Solid tumour/cancer [2A00-2F9Z] [12]
Epirubicin DMPDW6T Moderate Increased risk of prolong QT interval by the combination of Prochlorperazine and Epirubicin. Solid tumour/cancer [2A00-2F9Z] [12]
Vandetanib DMRICNP Major Increased risk of prolong QT interval by the combination of Prochlorperazine and Vandetanib. Solid tumour/cancer [2A00-2F9Z] [12]
Triptorelin DMTK4LS Moderate Increased risk of prolong QT interval by the combination of Prochlorperazine and Triptorelin. Solid tumour/cancer [2A00-2F9Z] [16]
Doxorubicin DMVP5YE Moderate Increased risk of prolong QT interval by the combination of Prochlorperazine and Doxorubicin. Solid tumour/cancer [2A00-2F9Z] [12]
Pitolisant DM8RFNJ Moderate Increased risk of prolong QT interval by the combination of Prochlorperazine and Pitolisant. Somnolence [MG42] [12]
Telavancin DM58VQX Moderate Increased risk of prolong QT interval by the combination of Prochlorperazine and Telavancin. Staphylococcal/streptococcal disease [1B5Y] [12]
Adenosine DMM2NSK Moderate Increased risk of ventricular arrhythmias by the combination of Prochlorperazine and Adenosine. Supraventricular tachyarrhythmia [BC81] [12]
Lenvatinib DMB1IU4 Moderate Increased risk of prolong QT interval by the combination of Prochlorperazine and Lenvatinib. Thyroid cancer [2D10] [12]
Cabozantinib DMIYDT4 Major Increased risk of prolong QT interval by the combination of Prochlorperazine and Cabozantinib. Thyroid cancer [2D10] [16]
Papaverine DMCA9QP Moderate Additive hypotensive effects by the combination of Prochlorperazine and Papaverine. Tonus and reflex abnormality [MB47] [22]
Tizanidine DMR2IQ4 Moderate Additive CNS depression effects by the combination of Prochlorperazine and Tizanidine. Tonus and reflex abnormality [MB47] [83]
Tacrolimus DMZ7XNQ Moderate Increased risk of prolong QT interval by the combination of Prochlorperazine and Tacrolimus. Transplant rejection [NE84] [12]
Atropine DMEN6X7 Moderate Additive anticholinergic effects by the combination of Prochlorperazine and Atropine. Unspecific substance harmful effect [NE6Z] [13]
Astemizole DM2HN6Q Moderate Increased risk of prolong QT interval by the combination of Prochlorperazine and Astemizole. Vasomotor/allergic rhinitis [CA08] [12]
Chlorpheniramine DM5URA2 Moderate Additive anticholinergic effects by the combination of Prochlorperazine and Chlorpheniramine. Vasomotor/allergic rhinitis [CA08] [13]
Methdilazine DMAUHQX Moderate Additive anticholinergic effects by the combination of Prochlorperazine and Methdilazine. Vasomotor/allergic rhinitis [CA08] [13]
Carbinoxamine DMCT31R Moderate Additive anticholinergic effects by the combination of Prochlorperazine and Carbinoxamine. Vasomotor/allergic rhinitis [CA08] [13]
Trimeprazine DMEMV9D Moderate Additive anticholinergic effects by the combination of Prochlorperazine and Trimeprazine. Vasomotor/allergic rhinitis [CA08] [18]
Brompheniramine DMFOVSD Moderate Additive anticholinergic effects by the combination of Prochlorperazine and Brompheniramine. Vasomotor/allergic rhinitis [CA08] [13]
Acrivastine DMTIGA0 Moderate Additive anticholinergic effects by the combination of Prochlorperazine and Acrivastine. Vasomotor/allergic rhinitis [CA08] [13]
Azatadine DMZ80SB Moderate Additive anticholinergic effects by the combination of Prochlorperazine and Azatadine. Vasomotor/allergic rhinitis [CA08] [13]
Procainamide DMNMXR8 Major Increased risk of prolong QT interval by the combination of Prochlorperazine and Procainamide. Ventricular tachyarrhythmia [BC71] [12]
Propafenone DMPIBJK Moderate Increased risk of prolong QT interval by the combination of Prochlorperazine and Propafenone. Ventricular tachyarrhythmia [BC71] [12]
Flecainide DMSQDLE Moderate Increased risk of prolong QT interval by the combination of Prochlorperazine and Flecainide. Ventricular tachyarrhythmia [BC71] [12]
Amiodarone DMUTEX3 Major Increased risk of prolong QT interval by the combination of Prochlorperazine and Amiodarone. Ventricular tachyarrhythmia [BC71] [12]
⏷ Show the Full List of 297 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
Allura red AC dye E00338 33258 Colorant
FD&C blue no. 2 E00446 2723854 Colorant
Quinoline yellow WS E00309 24671 Colorant
Sodium lauryl sulfate E00464 3423265 Emulsifying agent; Modified-release agent; Penetration agent; Solubilizing agent; Surfactant; lubricant
Stearic acid E00079 5281 Emulsifying agent; Solubilizing agent; Viscosity-controlling agent; lubricant
Sunset yellow FCF E00255 17730 Colorant
Carmellose sodium E00625 Not Available Disintegrant
Ferric hydroxide oxide yellow E00539 23320441 Colorant
Hypromellose E00634 Not Available Coating agent
Lactose monohydrate E00393 104938 Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate E00208 11177 lubricant
Polyethylene glycol 4000 E00654 Not Available Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polysorbate 80 E00665 Not Available Dispersing agent; Emollient; Emulsifying agent; Plasticizing agent; Solubilizing agent; Surfactant; Suspending agent
Silicon dioxide E00670 Not Available Anticaking agent; Opacifying agent; Viscosity-controlling agent
Titanium dioxide E00322 26042 Coating agent; Colorant; Opacifying agent
Triacetin E00080 5541 Humectant; Plasticizing agent; Solvent
Aluminum lake E00504 9989226 Other agent
Cellulose microcrystalline E00698 Not Available Adsorbent; Suspending agent; Diluent
⏷ Show the Full List of 18 Pharmaceutical Excipients of This Drug
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Prochlorperazine 10 mg tablet 10 mg Oral Tablet Oral
Prochlorperazine 5 mg tablet 5 mg Oral Tablet Oral
Prochlorperazine Maleate 5mg tablet 5mg Tablet Oral
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7279).
2 Prochlorperazine Prescribing Information - AA Pharma
3 BDDCS applied to over 900 drugs
4 Clinical pharmacology of prochlorperazine in healthy young males. Br J Clin Pharmacol. 1991 Dec;32(6):677-84.
5 Prochlorperazine - National Library of Medicine HSDB Database
6 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
7 Taylor WB, Bateman DN: Preliminary studies of the pharmacokinetics and pharmacodynamics of prochlorperazine in healthy volunteers. Br J Clin Pharmacol. 1987 Feb;23(2):137-42. doi: 10.1111/j.1365-2125.1987.tb03021.x.
8 ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
9 In vitro and in vivo characteristics of prochlorperazine oral disintegrating film. Int J Pharm. 2009 Feb 23;368(1-2):98-102.
10 Potential for drug interactions involving cytochromes P450 2D6 and 3A4 on general adult psychiatric and functional elderly psychiatric wards. Br J Clin Pharmacol. 2004 Apr;57(4):464-72.
11 Rescue of Pink1 Deficiency by Stress-Dependent Activation of Autophagy. Cell Chem Biol. 2017 Apr 20;24(4):471-480.e4. doi: 10.1016/j.chembiol.2017.03.005. Epub 2017 Mar 30.
12 Canadian Pharmacists Association.
13 Cohen MA, Alfonso CA, Mosquera M. Development of urinary retention during treatment with clozapine and meclizine [published correction appears in Am J Psychiatry 1994 Jun;151(6):952]. Am J Psychiatry. 1994;151(4):619-620. [PMID: 8147469]
14 Bateman DN, Rawlins MD, Simpson JM "Extrapyramidal reactions with metoclopramide." Br Med J (Clin Res Ed) 291 (1985): 930-2. [PMID: 3929968]
15 Product Information. Tibsovo (ivosidenib). Agios Pharmaceuticals, Cambridge, MA.
16 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
17 Product Information. Xospata (gilteritinib). Astellas Pharma US, Inc, Deerfield, IL.
18 Kulik AV, Wilbur R "Delirium and stereotypy from anticholinergic antiparkinson drugs." Prog Neuropsychopharmacol Biol Psychiatry 6 (1982): 75-82. [PMID: 7202232]
19 Beers MH, Ouslander JG, Rollingher I, Reuben DB, Brooks J, Beck JC "Explicit criteria for determining inappropriate medication use in nursing home residents." Arch Intern Med 151 (1991): 1825-32. [PMID: 1888249]
20 Cerner Multum, Inc. "Australian Product Information.".
21 Product Information. Clozaril (clozapine). Novartis Pharmaceuticals, East Hanover, NJ.
22 Aronowitz JS, Chakos MH, Safferman AZ, Lieberman JA "Syncope associated with the combination of clozapine and enalapril." J Clin Psychopharmacol 14 (1994): 429-30. [PMID: 7884028]
23 Product Information. Sirturo (bedaquiline). Janssen Pharmaceuticals, Titusville, NJ.
24 Product Information. Arcapta Neohaler (indacaterol). Novartis Pharmaceuticals, East Hanover, NJ.
25 Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982): 726-32. [PMID: 7042176]
26 Achor MB, Extein I "Diet aids, mania, and affective illness" Am J Psychiatry 138 (1981): 392. [PMID: 7468847]
27 Bock JL, Nelson JC, Gray S, Jatlow PI "Desipramine hydroxylation: variability and effect of antipsychotic drugs." Clin Pharmacol Ther 33 (1983): 322-8. [PMID: 6130865]
28 Ball P "Quinolone-induced QT interval prolongation: a not-so-unexpected class effect." J Antimicrob Chemother 45 (2000): 557-9. [PMID: 10797074]
29 Ban TA "Drug interactions with psychoactive drugs." Dis Nerv Syst 36 (1975): 164-6. [PMID: 1116424]
30 Eronen M, Putkonen H, Hallikainen T, Vartiainen H "Lethal gastroenteritis associated with clozapine and loperamide." Am J Psychiatry 160 (2003): 2242-2243. [PMID: 14638602]
31 Multum Information Services, Inc. Expert Review Panel.
32 Cole JM, Sheehan AH, Jordan JK "Concomitant use of ipratropium and tiotropium in chronic obstructive plmonary disease." Ann Pharmacother 46 (2012): 1717-21. [PMID: 23170031]
33 Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7. [PMID: 3725002]
34 Hanci V, Aydin M, Yurtlu BS, et.al "Anesthesia induction with sevoflurane and propofol: evaluation of P-wave dispersion, QT and corrected QT intervals." Kaohsiung J Med Sci 26 (2010): 470-7. [PMID: 20837343]
35 Product Information. Lamprene (clofazimine). Novartis Pharmaceuticals, East Hanover, NJ.
36 Avenoso A, Spina E, Campo G, Facciola G, Ferlito M, Zuccaro P, Perucca E, Caputi AP "Interaction between fluoxetine and haloperidol: Pharmacokinetic and clinical implications." Pharmacol Res 35 (1997): 335-9. [PMID: 9264051]
37 Nicholson SD "Extra pyramidal side effects associated with paroxetine." West Engl Med J 107 (1992): 90-1. [PMID: 1308691]
38 Product Information. Cymbalta (duloxetine). Lilly, Eli and Company, Indianapolis, IN.
39 Antonelli D, Atar S, Freedberg NA, Rosenfeld T "Torsade de pointes in patients on chronic amiodarone treatment: contributing factors and drug interactions." Isr Med Assoc J 7 (2005): 163-5. [PMID: 15792261]
40 Lee BS "Possibility of hyperpyrexia with antipsychotic and anticholinergic drugs." J Clin Psychiatry 47 (1986): 571. [PMID: 3771507]
41 Burke RE, Fahn S, Mayeux R, Weinberg H, Louis K, Willner JH "Neuroleptic malignant syndrome caused by dopamine-depleting drugs in a patient with Huntington disease." Neurology 31 (1981): 1022-5. [PMID: 6115336]
42 Product Information. Austedo (deutetrabenazine). Teva Pharmaceuticals USA, North Wales, PA.
43 Product Information. Ingrezza (valbenazine). Neurocrine Biosciences, Inc., San Diego, CA.
44 Product Information. Zonegran (zonisamide) Elan Pharmaceuticals, S. San Francisco, CA.
45 EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports.".
46 Product Information. Myrbetriq (mirabegron). Astellas Pharma US, Inc, Deerfield, IL.
47 Product Information. Enablex (darifenacin). Novartis Pharmaceuticals, East Hanover, NJ.
48 AbdelRahman SM, Gotschall RR, Kauffman RE, Leeder JS, Kearns GL "Investigation of terbinafine as a CYP2D6 inhibitor in vivo." Clin Pharmacol Ther 65 (1999): 465-72. [PMID: 10340911]
49 Product Information. Alphagan (brimonidine ophthalmic). Allergan Inc, Irvine, CA.
50 Product Information. Rukobia (fostemsavir). ViiV Healthcare, Research Triangle Park, NC.
51 Product Information. Stribild (cobicistat/elvitegravir/emtricitabine/tenofov). Gilead Sciences, Foster City, CA.
52 Product Information. Sustiva (efavirenz). DuPont Pharmaceuticals, Wilmington, DE.
53 Anson BD, Weaver JG, Ackerman MJ, et al. "Blockade of HERG channels by HIV protease inhibitors." Lancet 365 (2005): 682-686. [PMID: 15721475]
54 Postma JU, van Tilburg W "Visual hallucinations and delirium during treatment with amantadine (Symmetrel)." J Am Geriatr Soc 23 (1975): 212-5. [PMID: 123540]
55 Product Information. Xalkori (crizotinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
56 Blakely KM, Drucker AM, Rosen CF "Drug-induced photosensitivity-an update: Culprit drugs, prevention and management." Drug Saf 42 (2019): 827-47. [PMID: 30888626]
57 Product Information. Tagrisso (osimertinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
58 Abernethy DR, Wesche DL, Barbey JT, et al. "Stereoselective halofantrine disposition and effect: concentration-related QTc prolongation." Br J Clin Pharmacol 51 (2001): 231-7. [PMID: 11298069]
59 Harper KM, Knapp DJ, Criswell HE, Breese GR "Vasopressin and alcohol: A multifaceted relationship." Psychopharmacology (Berl) 235 (2018): 3363-79. [PMID: 32936259]
60 Ohnishi K, Yoshida H, Shigeno K, et al. "Prolongation of the QT interval and ventricular tachycardia in patients treated with arsenic trioxide for acute promyelocytic leukemia." Ann Intern Med 133 (2000): 881-5. [PMID: 11103058]
61 Product Information. Braftovi (encorafenib). Array BioPharma Inc., Boulder, CO.
62 Product Information. Zulresso (brexanolone). Sage Therapeutics, Inc., Cambridge, MA.
63 Product Information. Reyvow (lasmiditan). Lilly, Eli and Company, Indianapolis, IN.
64 Product Information. Addyi (flibanserin). Sprout Pharmaceuticals, Raleigh, NC.
65 Product Information. Farydak (panobinostat). Novartis Pharmaceuticals, East Hanover, NJ.
66 Product Information. Thalomid (thalidomide). Celgene Corporation, Warren, NJ.
67 Product Information. Zeposia (ozanimod). Celgene Corporation, Summit, NJ.
68 Product Information. Gleevec (imatinib mesylate). Novartis Pharmaceuticals, East Hanover, NJ.
69 Product Information. Belviq (lorcaserin). Eisai Inc, Teaneck, NJ.
70 Abernethy DR, Greenblatt DJ, Steel K, Shader RI "Impairment of hepatic drug oxidation by propoxyphene." Ann Intern Med 97 (1982): 223-4. [PMID: 7103282]
71 Lake CR "Manic psychosis after coffee and phenylpropanolamine." Biol Psychiatry 30 (1991): 401-4. [PMID: 1912131]
72 Sekar M, Mimpriss TJ "Buprenorphine, benzodiazepines and prolonged respiratory depression." Anaesthesia 42 (1987): 567-8. [PMID: 3592200]
73 Lambertsen CJ, Wendel H, Longenhagen JB "The separate and combined respiratory effects of chlorpromazine and meperidine in normal men controlled at 46 mm Hg alveolar pCO2." J Pharmacol Exp Ther 131 (1961): 381-93. [PMID: 13758472]
74 Mims RB, Scott CL, Modebe O, Bethune JE "Inhibition of L-dopa-induced growth hormone stimulation by pyridoxine and chlorpromazine." J Clin Endocrinol Metab 40 (1975): 256-9. [PMID: 1117978]
75 Hvizdos AJ, Bennett JA, Wells BG, Rappaport KB, Mendel SA "Anticholinergic psychosis in a patient receiving usual doses of haloperidol." Clin Pharm 2 (1983): 174-8. [PMID: 6883947]
76 Product Information. Nuplazid (pimavanserin). Accelis Pharma, East Windsor, NJ.
77 Product Information. Macrilen (macimorelin). Aeterna Zentaris, Charleston, SC.
78 Product Information. Zytiga (abiraterone). Centocor Inc, Malvern, PA.
79 Ansari SR, Chopra N "Gatifloxacin and Prolonged QT Interval." Am J Med Sci 327 (2004): 55-6. [PMID: 14722399]
80 Product Information. Celebrex (celecoxib). Searle, Chicago, IL.
81 Bluhm RE, Wilkinson GR, Shelton R, Branch RA "Genetically determined drug-metabolizing activity and desipramine- associated cardiotoxicity: a case report." Clin Pharmacol Ther 53 (1993): 89-95. [PMID: 8422746]
82 Product Information. Barhemsys (amisulpride). Acacia Pharma, Inc, Indianapolis, IN.
83 Product Information. Zanaflex (tizanidine). Acorda Therapeutics, Hawthorne, NY.